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Abstract

The physics of proton therapy has advanced considerably since it was
proposed in 1946. Today analytical equations and numerical simulation
methods are available to predict and characterize many aspects of proton
therapy. This article reviews the basic aspects of the physics of proton therapy,
including proton interaction mechanisms, proton transport calculations, the
determination of dose from therapeutic and stray radiations, and shielding
design. The article discusses underlying processes as well as selected
practical experimental and theoretical methods. We conclude by briefly
speculating on possible future areas of research of relevance to the physics
of proton therapy.
Keywords: proton therapy, interaction mechanism, transport, Monte Carlo,
dosimetry, shielding
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1. Introduction
The history of proton therapy began in 1946 when Robert Wilson published a seminal paper in
which he proposed to use accelerator-produced beams of protons to treat deep-seated tumors
in humans (Wilson 1946). In that paper, he explained the biophysical rationale for proton
therapy as well as the key engineering techniques of beam delivery. In 1954, the first human
was treated with proton beams at the Lawrence Berkeley Laboratory (Lawrence et al 1958).
In 1962, specialized radiosurgical proton treatments commenced at the Harvard Cyclotron
Laboratory (Kjellberg et al 1962a, 1962b), followed in the mid 1970s by treatments for ocular
cancers (Gragoudas et al 1982) and larger tumors (Koehler et al 1977). Physicists at Harvard,
collaborating with clinical colleagues at Massachusetts General Hospital, the Massachusetts
Eye and Ear Infirmary, and elsewhere, developed much of the physics and technology needed
to treat patients with proton beams safely and effectively. Remarkably, the research and development program at Harvard continued for more than 40 years (Wilson 2004). During the same
period, physicists elsewhere were developing other key technologies, including accelerators,
magnetically scanned beams, treatment planning systems, computed tomographic imaging
(CT), and magnetic resonance imaging.
The widespread adoption of proton therapy has been slow in comparison to, for example, intensity-modulated photon therapy. There are several reasons for this slow adoption of
proton therapy, including technical difficulty, cost, and lack of evidence of cost-competitiveness. Commercial proton delivery systems had been contemplated for decades before they
finally appeared in 2001 after overcoming considerable difficulties. The cost of proton therapy
equipment remains much higher than that of comparable photon therapy equipment; the longanticipated economies of scale have not, as yet, materialized. Even in times of relative prosperity, the allocation of scarce resources to proton therapy has been constrained by relatively
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sparse evidence of its cost-competitiveness and cost-effectiveness (Goitein and Jermann 2003,
Peeters et al 2010, Lievens and Pijls-Johannesma 2013).
Despite these obstacles, much progress has been made. Today there are 16 proton therapy centers in operation in the United States and 46 centers worldwide (PTCOG 2014). The
Particle Therapy Cooperative Group (PTCOG) reported that at least 105,743 patients had been
treated worldwide by the end of 2013 (PTCOG 2014). The proton therapy community has
stepped up efforts to conduct clinical trials that compare outcomes after proton therapy with
those after other advanced technology radiation therapies (Duttenhaver et al 1983, Shipley
et al 1995, Desjardins et al 2003, Zietman et al 2010).
The central rationale for proton therapy is its superior spatial dose distribution in the patient.
In recent years, the advantage of protons over photons in providing a highly conformal and
uniform dose to a tumor has been largely diminished by advances in photon therapies, such as
intensity-modulated photon therapy and volumetric arc therapies (Weber et al 2009). However,
the relative advantage of proton therapy in sparing normal tissues has never been more apparent or important; in the United States, approximately 65% of adults and 80% of children survive 5 years after their cancer diagnosis (Valdivieso et al 2012). About half of cancer patients
receive radiotherapy as part of their treatment. Recent studies reported that the incidence of
treatment-related morbidity, including second cancers, cardiovascular disease, fertility complications, and other late effects, is alarmingly high in long-term survivors of cancer (Wilson et al
2005, Carver et al 2007, Armstrong et al 2009, Merchant 2009, Sauvat et al 2009, Newhauser
and Durante 2011, Olch 2013). Presently, about 3% of the US population are cancer survivors,
corresponding to 11 million people, a figure projected to grow to 18 million by 2022 (de Moor
et al 2013). For these reasons, there is increasing interest in exploiting the tissue-sparing capabilities inherent to proton therapy to reduce the burden of treatment-related complications on
patients and the healthcare system. An understanding of the physics and biology of radiogenic
late effects from proton therapy has started to emerge in the literature in the last decade.
This paper reviews the basic, essential physics underlying proton therapy. The literature
includes excellent reviews of various aspects of proton therapy physics, most notably the
comprehensive work of Chu et al (1993), and also those of Bonnett (1993), Pedroni et al
(1995), Brahme (2004), Lomax (2009), Coutrakon (2007), and Schardt and Elsasser (2010)
In addition, several reports (ICRU 1998, 2007) and textbooks (Scharf 1994, Breuer and Smit
2000, DeLaney and Kooy 2008, Linz 2012, Paganetti 2012, Ma and Lomax 2013, Moyers and
Vatnitsky 2012) have covered various aspects of proton therapy physics. In recent years, many
textbooks dealing with general radiation oncology have included relevant chapters on proton
therapy (Van Dyk 1999, Halperin et al 2008, Pawlicki et al 2011). Many of the older works
on proton therapy have withstood the test of time and remain excellent literature resources of
continued relevance. However, in this review we mainly focus on the well-established basic
physics of proton therapy and on selected advances from the last 15 years or so that are important in clinical proton therapy. In choosing advances to cover in this review, considerable
selectivity was necessary because of the huge expansion of the proton therapy literature, especially in recent years. To the authors of the many studies that we were not able to mention in
this review because of space limitations, we apologize and we appreciate your understanding.
2. Proton interaction mechanisms
In this section, we briefly review the predominant types of interactions of protons in matter and
why they are important. Figure 1 illustrates several mechanisms by which a proton interacts
with an atom or nucleus: Coulombic interactions with atomic electrons, Coulombic interactions
R157
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Figure 1. Schematic illustration of proton interaction mechanisms: (a) energy loss

via inelastic Coulombic interactions, (b) deflection of proton trajectory by repulsive
Coulomb elastic scattering with nucleus, (c) removal of primary proton and creation
of secondary particles via non-elastic nuclear interaction (p: proton, e: electron, n:
neutron, γ: gamma rays)

with the atomic nucleus, nuclear reactions, and Bremsstrahlung. To a first-order approximation, protons continuously lose kinetic energy via frequent inelastic Coulombic interactions with
atomic electrons. Most protons travel in a nearly straight line because their rest mass is 1832
times greater than that of an electron. In contrast, a proton passing close to the atomic nucleus
experiences a repulsive elastic Coulombic interaction which, owing to the large mass of the
nucleus, deflects the proton from its original straight-line trajectory. Non-elastic nuclear reactions between protons and the atomic nucleus are less frequent but, in terms of the fate of an
individual proton, have a much more profound effect. In a nuclear reaction, the projectile proton
enters the nucleus; the nucleus may emit a proton, deuteron, triton, or heavier ion or one or
more neutrons. Finally, proton Bremsstrahlung is theoretically possible, but at therapeutic proton
beam energies this effect is negligible. Table 1 summarizes the proton interaction types, interaction targets, principal ejectiles, influence on the proton beam, and dosimetric manifestations. We
review these interaction mechanisms, except proton Bremsstrahlung, in the following sections.
2.1. Energy loss rate

The energy loss rate of ions, or linear stopping power, is defined as the quotient of dE and
dx, where E is the mean energy loss and x is the distance. It is frequently more convenient to
R158
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Summary of proton interaction types, targets, ejectiles, influence on
projectile, and selected dosimetric manifestations.

Table 1.

Influence on
projectile

Dosimetric
manifestation

Primary proton,
ionization
electrons

Quasi-continuous
energy loss

Energy loss
determines range in
patient

Atomic nucleus

Primary proton,
recoil nucleus

Change in
trajectory

Determines
lateral penumbral
sharpness

Non-elastic
nuclear reactions

Atomic nucleus

Secondary
protons and
heavier ions,
neutrons, and
gamma rays

Removal of
primary proton
from beam

Primary fluence,
generation of stray
neutrons, generation
of prompt gammas
for in vivo
interrogation

Bremsstrahlung

Atomic nucleus

Primary proton,
Bremsstrahlung
photon

Energy loss,
change in
trajectory

Negligible

Interaction type

Interaction target

Principal ejectiles

Inelastic
Coulomb
scattering

Atomic electrons

Elastic Coulomb
scattering

express the energy loss rate in a way that is independent of the mass density; the mass stopping
power is defined as
S
dE
,
 =−
ρ
ρdx

(1)

where ρ is the mass density of the absorbing material. Please note that stopping power is
defined for a beam, not a particle.
The energy loss rate may be described by several mathematical formulae. The simplest,
yet still remarkably accurate, formula is based on the Bragg–Kleeman (BK) rule (Bragg and
Kleeman 1905), which was originally derived for alpha particles, and is given by
S
dE
E1 − p
,
≈−
 =−
ρ
ρdx
ραp

(2)

where ρ is the mass density of the material, α is a material-dependent constant, E is the energy
of the proton beam, and the exponent p is a constant that takes into account the dependence of
the proton’s energy or velocity. Values of α and p may be obtained by fitting to either ranges
or stopping power data from measurements or theory.
A more physically complete theory, developed by Bohr (1915), is based on calculation of
the momentum impulse of a stationary, unbound electron and the impact parameter. A more
accurate formula, attributed to Bethe (1930) and Bloch (1933), takes into account quantum
mechanical effects and is given by
dE
Z z 2 ⎡ 2m ec 2γ 2β2
S
δ C⎤
ln
= 4πNAre2m ec 2
− β2 − − ⎥ ,
 =−
2 ⎢
2 Z⎦
Aβ ⎣
I
ρ
ρdx

(3)

where NA is Avogadro’s number, re is the classical electron radius, me is the mass of an electron, z is the charge of the projectile, Z is the atomic number of the absorbing material, A is the
R159

Topical Review

Phys. Med. Biol. 60 (2015) R155

Figure 2. Mass stopping power (S) versus ion energy (E) for protons in liquid water. The
corresponding range (R), calculated using the plotted S values and on the assumption of
the CSDA, is also plotted.

atomic weight of the absorbing material, c is speed of light, β = v/c where v is the velocity of
the projectile, γ = (1 − β2)−1/2, I is the mean excitation potential of the absorbing material, δ is
the density corrections arising from the shielding of remote electrons by close electrons and
will result in a reduction of energy loss at higher energies, and C is the shell correction item,
which is important only for low energies where the particle velocity is near the velocity of the
atomic electrons. The two correction terms in the Bethe–Bloch equation involve relativistic
theory and quantum mechanics and need to be considered when very high or very low proton
energies are used in calculations. Figure 2 plots proton stopping power as a function of proton
energy in water calculated by using equation (3) at high proton energies (above about 1 MeV)
and other methods (not presented) at lower energies.
It is instructive to observe in equation (3) how the projectile’s characteristics govern its
energy loss rate: energy loss is proportional to the inverse square of its velocity (1/v2 classically and 1/β2 relativistically) and the square of the ion charge (z = 1 for protons), and there
is no dependence on projectile mass. Similarly, equation (3) reveals that the absorber material can also strongly influence the energy loss rate. Specifically, the linear stopping power is
directly proportional to the mass density. It is equivalent, but perhaps more physically meaningful, to state that the linear stopping power is proportional to the density of electrons in the
absorber (NA ρ Z/A), because the energy loss occurs by Coulombic interactions between the
proton and atomic electrons. Z/A varies by only about 16%, from 0.5 for biologic elements
such as carbon and oxygen to 0.42 for high-Z beamline components, such as lead. Hydrogen
is an obvious exception to this; fortuitously, the concentration of hydrogen in the human body
is low (only about 10%) and nearly uniform throughout the body. The stopping power also
depends on a material’s I value, and the I value depends in a monotonic way on the Z of the
absorber, varying from about 19 eV for hydrogen to about 820 eV for lead. However, the stopping power goes with the logarithm of I−1 value, so the dependence is diminished. Hence,
putting these various dependencies in perspective, it is clear that the proton energy loss rate
in the human body depends most strongly on the material density, which can vary by about
R160
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three orders of magnitude, from air in the lung to cortical bone, and the ion velocity, which
can cause the linear stopping power in water to vary by about a factor of 60 for proton energies
between 1 and 250 MeV.
The stopping power theory for protons and heavier ions was reviewed by Ziegler et al
(1985, 1999, 2008) and in Report 49 of the International Commission on Radiation Units
and Measurement (1993). Evaluated stopping power and range tables may be conveniently
calculated with the SRIM code (‘Stopping and Ranges of Ions in Matter,’ computer program,
www.srim.org).
Thus far, we have described proton energy loss in an approximate way on the assumptions that a proton loses energy along a 2D line trajectory and that energy loss is continuous.
Absorption of this same energy, however, occurs in a 3D volume. Furthermore, the ionization
track of a proton has an irregular 3D structure caused by random fluctuations in the location
and size of primary ionization events. This is caused mainly by proton-produced recoil electrons, some of which are sufficiently energetic to create small spur tracks of ionization emanating from the main track. Because the electrons are very much lighter than the protons, each
interaction can reduce the proton energy only a little. The maximum possible energy transfer
in a collision of an ion of mass m with an unbound stationary electron is
Δ1max =

⎡
2m ec 2β2 ⎢
m
1+2 e
1 − β2 ⎢⎣
M

⎤
⎛ m ⎞2
+ ⎜ e⎟ ⎥,
1 − β2 ⎝ M ⎠ ⎥⎦
1

(4)

where me is the mass of an electron, M is the mass of the target material, c is the speed of light,
and β = v/c where v is the velocity of the projectile.
Even for very energetic protons, the secondary electrons do not acquire enough energy
to travel more than a few millimeters from the proton track. For example, at 200 MeV
proton energy, the maximum secondary electron energy is around 500 keV, which corresponds to an electron range of approximately 2 mm in water. The probability of producing
secondary electrons may be calculated with various total or differential cross-sections;
these were reviewed in ICRU Report 55 (1995). Track structure models may be used to
estimate the radial properties of ions (Kraft et al 1999), although this has not found common application in clinical proton therapy. Regardless of the calculation method used, the
spatial characteristics of secondary charged particles should, in principle, be taken into
account near material interfaces (e.g. buildup effects in transmission beam monitoring
instruments, skin, air–tumor interfaces in the lung) and in cases where the radiation quality
is of interest (e.g. microdosimetric and nanodosimetric characterization of individual dose
deposition events).
Finally, we note that in proton therapy water is considered an excellent tissue substitute
because of its similar density, effective Z/A, and other properties. Furthermore, proton energy
loss and residual range in various materials are often expressed in terms of their water-equivalent values. We discuss this in detail in section 3.1, but until then, for simplicity, we consider
water as being perfectly equivalent to tissue.
2.2. Range

Range is defined as the depth at which half of protons in the medium have come to rest,
as shown in the range-number curve plotted in figure 3. There are small variations in the
energy loss of individual protons (an effect called range straggling, which is discussed in
the following section). Consequently, the range is inherently an average quantity, defined
for a beam and not for individual particles. By convention, this means half of the protons
R161
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Figure 3. Relative fraction of the fluence Φ in a broad beam of protons remaining

as a function of depth z in water. The gradual depletion of protons from entrance to
near the end of range is caused by removal of protons from nuclear reactions. The
rapid falloff in the number of protons near the end of range is caused by ions running
out of energy and being absorbed by the medium. The sigmoid shape of the distal
falloff is caused by range straggling or by stochastic fluctuations in the energy loss
of individual protons.

incident on the absorber are stopped, although in some cases this is taken instead to mean
half of the protons survived to near the end of range (i.e. neglecting protons removed by
nuclear reactions).
The path of most protons in matter is a nearly straight line. On average, the proton’s pathlength is very nearly equal to its projected pathlength and range. This simple but important
fact renders many proton range calculations tractable with relatively simple numerical or analytical approaches.
Let us first consider a simple numerical calculation of proton beam range. We use proton
stopping power data and perform a 1D proton pathlength transport calculation on the assumptions that the ions travel only straight ahead (negligible lateral scattering) and that the protons
lose energy in a continuous matter. (These assumptions are reasonable for many clinical calculations, but we examine then relax these assumptions in later sections.) In this case, the range
(R) may be calculated as
E

R(E ) =

∫
0

⎛ dE ′ ⎞
⎛ dE ′ ⎞−1
⎜
⎟ dE ′ ≈ ∑⎜
⎟ ΔE ′ ,
⎝ dx ⎠
⎝ dx ⎠
−1

E

(5)

0

where E is the ion’s initial kinetic energy. The summation denotes that the continuous transport is approximated by calculations of discrete steps. In fact, as discussed above, this equation actually gives the pathlength, which is an excellent approximation of range in most
clinical situations. Figure 2 plots proton range in water calculated by using equation (5).
Next, we calculate the proton range using an analytical approach, which may be faster and
more practical than the numerical approach for many clinical calculations. We begin by noting
R162
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Figure 4. Energy loss PDFs are plotted for various thicknesses of water absorbers,

where the thickness is expressed in units of mean free path (mfp). For visual clarity, the
energy-loss PDFs have been scaled on both the abscissa and ordinate. The single event
energy loss is expressed as a fraction of the mean energy lost in the entire absorber
thickness, or (Δ − Δav) / Δav. Each PDF was scaled so that the integral over all energyloss values yields unit value. For thin absorbers (curves a–e), the PDFs are broader
and asymmetric and are modeled with the Vavilov (1957) or Landau (1944) theories.
For thick absorbers (curve f), the PDFs are symmetric and well-approximated with
Bohr’s theory (1915), i.e. a Gaussian distribution (reproduced with permission from
ICRU 1993).

that the interval of proton range of interest typically extends from 1 mm (about the size of a
voxel in an anatomic image of patient anatomy) to about 30 cm (about the midline of a large
adult male’s pelvis, the deepest site in the human body). These ranges correspond to 11 MeV
and 220 MeV, respectively, as seen in figure 2. More importantly, figure 2 reveals that the
relationship between the logarithm of range and logarithm of energy is almost linear. This is
fortuitous because this means that the range follows a very simple power law, as realized by
Bragg and Kleeman (1905) and others early in the last century. Thus, the range of a proton
may be calculated using the Bragg–Kleemann rule, or
R(E )= αE p,

(6)

where, as before, α is a material-dependent constant, E is the initial energy of the proton beam,
and the exponent p takes into account the dependence of the proton’s energy or velocity.
The uncertainty in proton range depends on many factors. For example, the uncertainty
in a range measurement depends on the precision and accuracy of the measurement apparatus and, in some cases, on the experimenter’s skill. A common concern in clinical proton
therapy is the uncertainty in calculated range, e.g. in calculating the settings of the treatment
machine for a patient’s treatment. The uncertainty in range may depend on the knowledge of
the proton beam’s energy distribution and on properties of all range absorbing materials in
the beam’s path. These properties include elemental composition, mass density, and linear
R163
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stopping power. The linear stopping powers deduced from computed tomography scans have
many additional sources of uncertainty, including imperfections in the calibration of CT scanners (i.e. the method used to convert image data from Hounsfield Units to linear stopping
power), partial volume effects, motion artifacts, and streaks artifacts.
2.3. Energy and range straggling

In the preceding sections, we approximated the energy loss rate by assuming that the slowing
of ions occurs in a smooth and continuous manner. In fact, we considered the mean energy
loss rate and neglected variations in the energy loss rates of individual protons. For many
clinical calculations, these assumptions are valid and lead to a reasonably good first-order
approximation. However, the accumulation of many small variations in energy loss, termed
energy straggling or range straggling, is one of the physical processes that strongly governs
the shape of a proton Bragg curve, a subject that will be covered in section 3.2. Thus, an
understanding of range straggling is key to understanding the characteristics of proton dose
distributions.
Figure 4 plots the relative energy loss probability density functions (PDFs) for protons
transmitted through water absorbers of various thickness. The curves have been normalized to
enhance visual clarity. Apparently, thick absorbers result in a symmetric distribution of energy
losses, whereas thin absorbers yield curves that are asymmetric with modes less than the mean
and long tails of large energy losses. In principle, straggling PDFs may be calculated numerically from first principles, but usually theoretical approaches are used. Later in the section,
three of the most commonly used straggling theories are described.
Having examined the mean energy loss rate in modest detail (section 2.1), and having
conceptually introduced energy straggling, it is instructive to understand how these effects
are related mathematically before delving into straggling theory. To understand these relationships, let us consider the moments of the ion energy PDF, or
max

Δ1

Mn =

∫

Δn f (Δ)dΔ,

(7)

0

where Δ is the energy loss of an ion in traversing an absorber, f(Δ)dΔ is the probability of energy
loss occurring in the interval from Δ to Δ + dΔ, n is the order of the moment, and Δ1max is from
equation (14). The zeroth moment is the total collision cross section, the first moment is the
(mean) electronic stopping power, the second moment corresponds to the width (variance)
of the energy straggling distribution, the third moment to its asymmetry (skewness), and the
fourth to its kurtosis. The variance, sometimes denoted by σΔ2, or second moment of the straggling distribution f(Δ), is
max

Δ1

M2(Δ)= σΔ2 = v

∫

Δ2 f1 (Δ)dΔ,

(8)

0

where v̄ is the average number of primary collisions per proton traversal. A more detailed discussion of the straggling moments was given by Rossi and Zaider (1996).
Next we examine theories for calculating energy straggling proposed by Bohr (1915),
Landau (1944), and Vavilov (1957). These theories are valid for thick, intermediate, and thin
absorbers, respectively. The criterion for selecting a valid theory for a given absorber thickness is based on a reduced energy loss parameter,
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k =

ξ
Δ1max

,

(9)

where ξ is the approximate mean energy loss and Δ1max is the maximum energy loss possible
in a single event.
According to Bohr’s theory, the energy straggling distribution behaves according to a
Gaussian PDF, or
1
−(Δ − Δ )2
exp
,
2σΔ2
σΔ 2π

f (Δ)dΔ =

(10)

where for non-relativistic ions the variance is given by
σ Δ2 = 2πre2m ec 2z 2

NZ max
Δ1 ρx,
β2

(11)

where p is the mass density and x is the thickness of the absorber. Bohr’s theory assumes that
the absorber is thick enough that there are many individual collisions (i.e. the central limit theorem holds), that the ion velocity does not decrease much in crossing the absorber, and that the
absorber is made of unbound electrons. For most applications in proton therapy, Bohr’s theory
provides adequate accuracy. Several authors have reported convenient power law approximations to estimate sigma as a function of the proton beam range (Chu et al 1993), or
σ Δ ≈ kR0m,

(12)

where R0 is the range in water in centimeters for a mono-energetic proton beam, k is a
 aterial-dependent constant of proportionality, and the exponent is empirically determined.
m
For protons in water, k = 0.012 and m = 0.935 (Bortfeld 1997).
Landau’s theory relaxed the assumption that the central limit holds, i.e. there are relatively
fewer individual collisions in an intermediate thickness absorber, and used an approximate
expression for Δ1. In this case, we have
f (Δ, ρx )dΔ =

1
φ L(λL ),
ξ

(13)

where the parameter ϕL(λL) roughly corresponds to the deviation from the mean energy loss
and was defined by Landau as
φ
 L(λL )=

1
π

∞

∫ e−y(lny−λ )sin(πy)dy .
L

(14)

0

Evaluation of the integral in equation (14) is straightforward and the reader is referred to
the literature for details (Seltzer and Berger 1964).
Vavilov’s theory is in essence a generalization of Landau’s theory that utilizes the correct
expression for Δ1 and is given by
f (Δ, ρx )dΔ =

1
φ V(λV, k , β2 )dλV,
ξ

(15)

where
1 k (1 + β 2γ )
φ
 V(λV, k , β )= e
π
2

∞

∫ ekf cos(λVy + kf2 )dy,
1

0
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Figure 5. Schematic diagram showing the trajectory of a proton undergoing multiple

Coulomb scattering events. θ is the root mean square (rms) space scattering angle and
θx is the projected rms scattering angle (reproduced with permission from Leo 1994).

and
λV =

Δ−Δ
− k(1 + β2 − γ ),
Δ1max

(17)

where γ is Euler’s constant. The evaluation of Vavilov’s theory is computationally more expensive than that of Bohr’s or Landau’s. For additional details, the reader is referred to Vavilov’s
original work (Vavilov 1957).
2.4. Multiple Coulomb scattering

As illustrated in figure 5, a proton passing close to the nucleus will be elastically scattered or
deflected by the repulsive force from the positive charge of the nucleus. While the proton loses
a negligible amount of energy in this type of scattering, even a small change in its trajectory
can be of paramount importance. In fact, it is necessary to take into account Coulomb scattering when designing beamlines and treatment heads (Gottschalk 2010b) and in calculations of
dose distributions in phantoms or patients, e.g. with treatment planning systems (Hong et al
1996, Pedroni et al 2005, Schaffner 2008, Koch and Newhauser 2010).
To characterize the amount that a beam is deflected by scattering, we use the quantity of
scattering power, which is defined as
T
 =d< θ 2 >/dx,

(18)

where < θ > is the mean squared scattering angle and x is the thickness of absorber through
which the proton has traveled. Similarly, the mass scattering power is simply T/ρ, where ρ is
the mass density of the absorber material. Notice that the definition of scattering power utilizes the mean square of the scattering angle; scattering is symmetric about the central axis,
and therefore the mean scattering angle is zero and contains no useful information. Also, note
that the value of the scattering power depends on the material properties and dimensions of
the absorber being considered.
Predictions of elastic Coulomb scattering are commonly classified according to the number of individual scattering events (Ns) that occur in a given absorber. For single scattering
(Ns = 1), Rutherford scattering theory applies. Plural scattering (1 < Ns < 20) is difficult to
model theoretically and is not discussed further here. For multiple Coulomb scattering (MCS;
Ns ≥ 20), the combined effect of all Ns scattering events, may be modeled by using a statistical
approach to predict the probability for a proton to scatter by a net angle of deflection, commonly denoted by θ (figure 5).
2
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It is instructive to briefly examine Rutherford’s theory of single scattering (Rutherford
1911). The differential cross section dσ for scattering into the solid angle dΩ is given by
(m c / β p ) 2
dσ
,
= z12z22re2 e 4

dΩ
4sin (θ / 2)

(19)

where z1 is the charge of the projectile, z2 is the atomic number of the absorber material, re is
the classical electron radius, me is the mass of the electron, c is the speed of light, β = v/c, p is
the ion momentum, and θ is the scattering angle of the proton. The angular dependence is governed by the term 1/sin4(θ/2), i.e. in individual scattering events, the proton is preferentially
scattered in the forward direction, at very small angles.
In clinical proton therapy, most objects of interest are thick enough to produce a great many
scattering events. Thus, for clinical proton therapy, we are usually more interested in the net
effect that many small-angle scattering events have on many protons, e.g. how beamline scattering in the treatment head influences the spatial distribution of dose in a patient.
Rigorous theoretical calculations of MCS are quite complex. The most complete theory
was proposed by Molière (1948). Assuming that scattered particles are emitted at small deflection angles (i.e. the small-angle approximation in which sin(θ) ≈ θ),
⎛
F1(η)
F (η ) ⎞
+ 2 2 ...⎟ ,
P(θ ) d (Ω ) = ηdη ⎜2exp(−η2 )+
⎝
⎠
B
B

(20)

where η = θ / (θ1 B1/2), θ1 = 0.3965 (zZ/pβ) ρδx / A and d(Ω) is the solid angle into which the
particles are scattered. The functions Fk(η) are defined as
F
 k (η ) =

1
k!

⎛

∫ J0(ηy) exp ⎜⎝ −4y

2⎞⎡ 2

k
y ⎛ y2 ⎞ ⎤
⎟ ⎢ ln ⎜ ⎟ ⎥ y dy,
⎠⎣ 4 ⎝ 4 ⎠ ⎦

(21)

where Jo(ηγ) is a Bessel function. Values of Fi have been tabulated in the literature by several
authors. Parameter B in equation (20) may be found by numerical methods, by solving
g (B ) = ln B – B + ln γ – 0.154 = 0,

(22)

where γ = 8831 q z ρδx/(β AΔ) and Δ = 1.13+3.76 (Zz/137β) . The following are symbols
representing properties of the absorber: Z is the atomic number, A is the atomic mass, δx is the
thickness, and ρ is the mass density. The proton momentum is denoted by p, β = ν/c, and z = 1
is the proton charge. Even though we have not presented all of the details, clearly the evaluation
of Molière’s theory is indeed complex. Consequently, considerable attention has been paid in
the literature to developing simpler formulae; the simplicity usually comes at the cost of reduced
accuracy in modeling scattering at large angles. Gottschalk et al (1993) discussed several of
these methods in detail. One approximation method takes the form of a Gaussian distribution,
2

P(
 θ) ≈

2

2

⎛ −θ 2 ⎞
2θ
exp
⎜
⎟ dθ ,
⎝ < θ2 > ⎠
< θ2 >

(23)

where (< θ2 >)1/2 is the root mean square (rms) scattering angle or the width parameter of the
Gaussian distribution.
Gottschalk (2010b) proposed a differential approximation to Molière’s theory to predict
the scattering power according to
⎛ ES ⎞2 1
,
T
 dM = fdM (pv, p1 v1)× ⎜ ⎟
⎝ pv ⎠ XS
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Figure 6. Broadening of the beam width in water due to multiple Coulomb scattering

(reproduced with permission from Pedroni et al 2005).

where ES = 15 MeV, p is the momentum and ν is the velocity of the proton, p1 and v1 are the
initial momentum and velocity, XS is scattering length of the material, and fdM is a materialindependent nonlocal correction factor given by

(

)

fdM = 0.5244 + 0.1975lg 1 − (pv / p1 v1) +

2
0.2320lg(pv )− 0.0098lg(pv )lg 1 − (pv / p1 v1) .
2

(

)

(25)

The factor fdM takes into account the accumulation of scattering that occurs as the proton
slows from v1 to ν and is material independent. The scattering length is given by
1
Z2
= αNre2 (2 log(33219(AZ )−1/3 − 1),

A
ρX S

(26)

where α is the fine structure constant, N is Avogadro’s number, re is electron radius, and Z, A,
and ρ are the atomic number, atomic weight, and density of the target material.
It is sometimes convenient to project the expected scattering angle < θ > in 3D space to the
corresponding value in a plane, denoted < θx > , according to
<
 θx >2 = < θx2 >/2.

(27)

Also, in proton therapy the lateral displacement (r) of a proton beam is typically calculated
from the scattering angle. Under the Gaussian approximation, we have
P (r ) dr = 6r (< θ 2 >t 2 )−1exp (−3r 2 / (< θ 2 >t 2 ) dr ,

(28)

where t = x/Lrad, and Lrad is the radiation length of the material, which can be calculated easily
or looked up in tables. The mean square lateral displacement is given by
 r 2 > = < θ 2 >t 2 / 3.
<

(29)
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Figure 7. Small implanted fiducial markers can create clinically significant dosimetric
cold spots in proton therapy beams. (Upper) 2D dose distribution as a function of
depth in water (z) and crossfield position (x) from a Monte Carlo simulation of rangemodulated proton beam incident on a water phantom containing tantalum localization
markers oriented (a, b) parallel to the beam axis and (c, d) perpendicular to the beam
axis. The range and modulation width are typical for uveal melanoma treatments.
(Lower) simulated absorbed dose (D) as a function of depth (z) in the water phantom
at various off-axis positions. The perturbed depth dose profiles are parallel to the beam
axis and pass through the center of markers a–d in the plot above. For visual clarity,
portions of the perturbed dose profiles upstream of the markers are not shown. An
unperturbed beam is plotted with open squares (reproduced with permission from
Newhauser et al 2007c).

A power law approximation for rms displacement of protons is
rrms = aR b,

(30)
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where a is a unitless material constant, R is the water-equivalent proton beam range in cm,
and the exponent b governs the range dependence. For protons in water, a = 0.0294 and
b = 0.896 (Chu et al 1993). Koehler and Preston derived a convenient expression to calculate
rrms as a function of depth in an absorber and knowledge of its maximum values, rmax, at the
end of range (from an unpublished manuscript; some portions of their work were reported by
Gottschalk (2010b)).
In proton therapy, MCS in the treatment head (i.e. in the scattering foils) is helpful because
it allows the beam to be spread laterally to useful dimensions, e.g. to make a beam laterally
large and flat so that a tumor may be completely covered with a uniform dose. Scattering foils
in the nozzle are carefully designed to utilize MCS and energy loss to produce clinically useful
beams (Koehler et al 1977, Gottschalk 2004) However, MCS in the treatment head and in the
patient blurs lateral penumbral sharpness. This is manifested as penumbral growth at the edge
of collimated beams and/or the growth of the lateral spot size of a scanned beam (figure 6).
Understanding and preserving penumbral sharpness is key to realizing the full benefit of proton therapy for sparing healthy tissue.
Recent studies have revealed that MCS plays an important role in proton dose distribution
around small implanted metal objects. Specifically, implanted fiducial markers for imageguided patient alignment have been used in proton therapy for many years (Gall et al 1993,
Welsh et al 2004, Newhauser et al 2007a, 2007c, Ptaszkiewicz et al 2010, Matsuura et al
2012). Substantial recent improvements in on-board imaging systems, patient positioning,
and patient immobilization have led to increased use of radiopaque implanted fiducial markers in proton therapy to many disease sites, with the goal of improving target coverage and/or
normal tissue sparing. However, recent studies revealed that some commonly used markers,
even those less than 1 mm in size, can cause severe cold spots (figure 7), compromising target
coverage (Newhauser et al 2007a, 2007c, Carnicer et al 2013). The severity of the cold spots
varies with fiducial size, material composition, and mass density. These parameters, in turn,
determine the amount of MCS and energy loss in the fiducial and, hence, perturbations to the
dose distribution in surrounding tissue. In essence, MCS in the fiducial causes a downstream
dose shadow that may be partially or fully filled in by MCS in the surrounding tissue. While
MCS is important, energy loss in the fiducial (or its water-equivalent thickness), the proximity
of the fiducial to the end of the proton beam range, and of course its size and orientation with
respect to the beam also should be considered. The physics of dose perturbations is explained
in detail elsewhere (Newhauser et al (2007a), and several subsequent studies (Giebeler et al
2009, Lim et al 2009, Cheung et al 2010, Huang et al 2011) have shown that it is possible to
achieve good radiographic visibility using novel markers that do not significantly perturb the
therapeutic dose distribution in tissue.
Others have examined the effects of MCS in larger metal objects on clinical proton beams
and characterized the suitability of approximate methods to predict MCS in practical clinical
applications (Herault et al 2005, Stankovskiy et al 2009, Newhauser et al 2013).
2.5. Nuclear interactions

In addition to the mechanisms already described, protons may interact with the atomic nucleus
via non-elastic nuclear reactions in which the nucleus is irreversibly transformed, e.g. a reaction in which a proton is absorbed by the nucleus and a neutron is ejected, denoted by (p,n).
The main effect of nuclear reactions within a therapeutic region of a proton field is a small
decrease in absorbed dose due to the removal of primary protons, which is compensated to a
large extent by the liberation of secondary protons and other ions. In this section, we discuss
this and several other important aspects of nuclear reactions.
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Figure 8. The total proton-induced non-elastic nuclear reaction cross section in oxygen
versus proton energy, showing a threshold corresponding to the Coulomb barrier at
approximately 6 MeV (reproduced with permission from ENDF 2011, Chadwick et al
2011).

Before discussing reaction mechanisms, it is instructive to examine a range-number curve
(figure 3), which plots the remaining number of protons versus depth in an absorber as a
beam comes to rest. The gradual depletion of protons from entrance to near the end of range
is caused by removal of protons by nuclear reactions. The rapid falloff in the number of protons near the end of range is caused by ions running out of energy and being absorbed by the
medium. The sigmoid shape of the distal falloff is caused by range straggling or by stochastic
fluctuations in the energy loss of individual protons.
To enter the nucleus, protons need to have sufficient energy to overcome the Coulomb barrier of the nucleus, which depends on its atomic number. The total non-elastic cross-section
for proton-induced nuclear reactions has a threshold, on the order of 8 MeV in the atomic
nuclei of biologically relevant elements, which rises rapidly to a maximum at around 20 MeV,
then asymptotically declines to about half the maximum value by about 100 MeV (figure 8).
Tabulated and graphical nuclear data may be obtained conveniently online from the Evaluated
Nuclear Data File (ENDF) (IAEA 2013). ICRU Report 63 also provides extensive nuclear
data for hadron therapy and radiation protection (ICRU 2000).
Several nuclear reactions are particularly important to clinical proton therapy and proton
therapy research. In a proton therapy beam, proton-induced reactions can produce energetic
protons, deuterons, tritons, 3He, 4He, and other ions. Secondary protons comprise as much as
about 10% of the absorbed dose in a high-energy proton treatment beam; they have a small but
non-negligible impact on the spatial dose distribution in a patient (Medin and Andreo 1997,
Boon 1998, ICRU 1998, Paganetti 2002, Wroe et al 2005). Deuterons and heavier ions are
present in much smaller proportions; collectively they comprise about 1% or less of the therapeutic absorbed dose (ICRU 1998). Their energy and range are very small and they deposit
their kinetic energy locally, i.e. very near their point of creation.
Relatively high-current protons beams are incident on certain beam production and delivery equipment and on some patients. These proton beams produce neutrons that create significant potential safety hazards. Great care must be taken to limit exposures of personnel to
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Figure 9. Schematic illustration of the concept of water equivalent thickness (WET)

and how it can be calculated or measured by observing changes in the depth of a proton
Bragg curve in a water tank (reproduced with permission from Zhang and Newhauser
2009).

neutrons (NCRP 1971, 1990, 1993, 2005, Newhauser and Durante 2011). Some electronic
systems must also be hardened, shielded, or located so that neutron radiation does not cause
soft upsets or permanent damage to semiconductor components. Attention must also be paid
to neutron activation of beamline components, air, groundwater, and other materials (IAEA
1988).
Neutrons are produced in copious quantities: they span 10 orders of magnitude in neutron
energy, their energy distributions depend strongly on the proton beam energy and direction,
they are extremely penetrating, and their relative biologic effectiveness is as much as about 20
times higher than that of proton radiation (ICRP 2007). Thus they potentially increase the risk
of radiogenic late effects (Hall 2006, Brenner and Hall 2008, Newhauser and Durante 2011).
Several specific aspects of neutron exposures are considered in a later section of this paper.
Nuclear reactions inside the patient may provide a non-invasive approach to measure a variety of beam and patient properties, such as proton beam range, elemental composition of tissues, and even intra- or inter-fraction physiology. The basic approach is to detect gamma rays
from proton-induced nuclear reactions, such as neutron capture reactions, denoted by (n, γ).
Approaches are under development that detect photons from positron annihilation, prompt
gammas, and delayed gammas. Gamma ray detection approaches have included positron emission tomography camera (Parodi et al 2007, Moteabbed et al 2011, Cho et al 2013, Min et
al 2013), Compton camera (Peterson et al 2010, Smeets et al 2012), 1D detector arrays (Min
et al 2012), and photon counting systems (Kim et al 2012). These techniques are in various
stages of research and development; none is routinely used in clinical practice. There remain
many challenges to overcome, including instrument sensitivity and calibration; interpretation
of measurements, including an understanding of managing measurement artifacts; and competition from alternative methods, e.g. magnetic resonance imaging techniques (Krejcarek et
al 2007, Raaymakers et al 2008, Gensheimer et al 2010).
3. Proton transport calculations
In this section, we review several aspects of proton transport physics that are encountered
frequently in clinical and research situations. We describe the 1D water-equivalent thickness
of an arbitrary material, the shapes of a pristine Bragg curve and a spread out Bragg peak
(SOBP) curve, and stray radiation exposures.
R172

Topical Review

Phys. Med. Biol. 60 (2015) R155

Table 2. Common materials (lung substitute plastic, high-density polyethylene
(HDPE), water, polystyrene, polymethylmethacrylate (PMMA), polycarbonate
resin (Lexan), bone substitute plastic, aluminum, titanium, stainless steel, lead
and gold) used in heavy charged particle beams, with their mass densities ρ,
values of (Z/A)eff, mole fractions and fitting parameters of α and p for these
materials when applying the BK rule. (The energies used in the fit were from
10 to 250 MeV).

Material

Ρ (g cm−3)

(Z/A)eff

Mole fraction (%)

α

p

H 55.577, C 32.738, N 0.927, O
7.508, Cl 0.019, Si 0.184, Mg 3.048
H 66.717, C 33.283
H 66.667, O 33.333
H 49.851, C 50.149
H 53.333, C 33.333, O 13.333,
H 42.424, C 48.485, O 9.091
H 35.215, C 29.592, N 0.803, O
26.695, Cl 0.16, Ca 7.679
Al 100
Ti 100
C 0.045, N 0.045, Si 0.450, Cr
18.150, Mn 1.250, Fe 71.460, Ni
8.550, Mo 0.050
Pb 100
Au 100

8.994 × 10–3

1.735

10–3
10–3
10–3
10–3
10–3
10–3

1.737
1.735
1.735
1.735
1.735
1.730

1.364 × 10–3
9.430 × 10–4
5.659 × 10–4

1.719
1.710
1.706

6.505 × 10–4
3.705 × 10–4

1.676
1.677

Lung substitute

0.3

0.537

HDPE
Water
Polystyrene
PMMA
Lexan
Bone substitute

0.964
1.0
1.06
1.185
1.20
1.829

0.570
0.555
0.538
0.539
0.527
0.516

Aluminum
Titanium
Stainless steel

2.698
4.519
7.85

0.482
0.459
0.466

11.322
19.311

0.396
0.401

Lead
Gold

2.541
2.633
2.545
2.271
2.310
1.666

×
×
×
×
×
×

3.1. Water-equivalent thickness

As we mentioned previously, in proton therapy water closely mimics the properties of
human tissues in terms of energy loss, MCS, and nuclear interactions. As such, water is a
recommended phantom material for dose and range measurements and reference material for
reporting corresponding calculated quantities (ICRU 1998, IAEA 2000). For example, it is a
common and convenient clinical practice to specify the penetrating power of a proton beam
by its range in water (ICRU 1998, 2007). In this way, range losses in various beamline objects
and the patient may be easily added or subtracted from one another in a physically consistent
and intuitive way. Viewed another way, it is also convenient to specify the range-absorbing
power of various objects in the beam path, e.g. beam transmission monitors and immobilization devices, by their equivalent thickness if they were made of water.
Water-equivalent thickness (WET) is often used to characterize the beam penetration range;
figure 9 schematically illustrates the concept of WET and how it can be calculated or measured.
For treatment sites with nearby critical structures, e.g. an optic nerve, the range of the planned
and delivered beams must agree within a few millimeters. To accomplish this, treatment planning systems are commonly configured with the WET values of all items not included in
the planning CT images, such as components in the treatment head, immobilization devices
not present during the CT scan, or a treatment couch (Newhauser et al 2007b). Similarly, to
determine the measurement geometry for patient-specific clinical quality assurance measurements, the WET of measurement instruments and possibly other devices must be determined
(Newhauser 2001a, 2001b). Thus, it is important to have methods to calculate and measure
WET. In this section, we emphasize recently developed calculation methods that are convenient and suitable for clinical calculations, using the energy loss theories presented in section 2.
R173

Topical Review

Phys. Med. Biol. 60 (2015) R155

5.8
5.6
5.4
5.2
WER

5.0
2.0
1.8
1.6
1.4
1.2

0.1 cm Pb
1.5 cm Pb
0.1 cm Al
1.5 cm Al
2 cm PMMA
10 cm PMMA

0

50

100

150

200

250

E (MeV)
Figure 10. Calculated WER values as a function of proton beam energy. This plot

illustrates the dependence of WER value on the target material, the beam energy, and
the target thickness (reproduced with permission from Zhang and Newhauser 2009).

Our discussion of WET measurement methods is very brief, mainly because they are relatively
simple and obvious. In practice, however, WET measurements remain very important (Andreo
2009, Gottschalk 2010a, Newhauser and Zhang 2010, Zhang et al 2010b, Besemer et al 2013,
Moyers et al 2010).
The IAEA (2000) proposed that WET can be approximated by
ρ
tw = tm m cm,
(31)
ρw
where the depth scaling factor, cm, can be calculated, to a good approximation, as the ratio of
the continuous slowing down approximation (CSDA) range (in g cm−2) in water to that in the
target:
c m =

ρw Rw
.
ρm Rm

(32)

Because the ranges in equation (32) correspond to complete loss of ion energy, this
approach is strictly valid only for stopping-length targets. An exact equation for WET that is
applicable to thin targets was reported by Zhang and Newhauser (2009):
tw = tm

ρm Sm
,
ρw Sw

(33)

where ρw and ρm are the mass densities of water and material, respectively, and Sm and Sw
are the mean proton mass stopping power values for the material and water, respectively,
defined by
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Figure 11. Central axis depth dose profiles from several particle beams. Note that these
distributions are from solitary beams in order to clearly compare the differences in the
physical properties of various radiations. The important features are that proton beams
offer relatively low entrance dose and virtually no exit dose. However, many clinical
treatment techniques exploit multiple field directions to enhance the uniformity of tumor
coverage and to spare sensitive healthy tissues. In fact, in some cases proton treatments
provide inferior skin sparing to photons and/or inferior target coverage, e.g. because of
proton beams’ sensitivity to range errors. Nonetheless, beam for beam, proton beams
provide excellent tissue sparing, especially beyond the end of range (reproduced with
permission from Larsson 1993).

S =

∫ S dE
E

∫ dE

.

(34)

E

For thin targets, where the proton loses a negligible fraction of its energy in the absorber
material, we have
αwpw p − p
E w m,
tw ≈ tm(ρm / ρw )(Sm / Sw ) = tm
(35)
αmpm
where the reader will recognize α and p from the discussion of the BK rule (see section 2.1).
Values of α and p for commonly encountered materials in proton therapy are provided in
table 2. Zhang and Newhauser (2009) also reported a slightly more complex analytical formula to calculate WET for targets of arbitrary thickness.
As can be seen in the curves of the water-equivalent ratio (WER = tw/tm) plotted in figure 10,
taking into account the target thickness in calculating WER is most important for absorbers
that are thick and made of high Z materials, e.g. lead scattering foils, and for protons that are
of comparatively low energy when impinging on the target. For low-Z materials, such as tissue
and plastic, WER depends only very weakly on the target thickness and initial proton beam
energy, and the approximate (thin and stopping length) analytical methods provide sufficient
accuracy for most clinical applications.
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Figure 12. Comparison of depth-dose curves from proton SOBPs and from electron
beams. Because the proton mass is nearly 2000 times that of an electron, proton
scattering interactions (individual angular deflections and variations in collisional
energy losses) are much smaller, leading to sharper lateral and distal falloff distances
(reproduced with permission from Koehler and Preston 1972).

Figure 13. Absorbed dose D as a function of depth z in water from an unmodulated

(pristine) proton Bragg peak produced by a broad proton beam with an initial energy
of 154 MeV. The various regions, depths, and lengths that are labeled are defined in the
text. (The electronic buildup is not visible in this plot.) This type of dose distribution
is useful clinically because of the relatively low doses delivered to normal tissues in
the sub-peak and distal-falloff regions relative to the target dose delivered by the peak.
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Figure 14. Absorbed dose D as a function of depth z in water from a spread-out proton

Bragg peak (SOBP). Various locations and regions that are indicated on the plot are
defined in the text. This peak was measured with a Markus-type parallel-plate ionization
chamber in the Northeast Proton Therapy Center (NPTC) gantry. The measured data
are plotted with open circles and the model-fit as a solid line. Note that the electronic
buildup region, which spans only a few millimeters, is not visible in this plot.

3.2. Features of pristine and spread-out Bragg curves

The spatial dose distribution from clinical proton therapy beams is quite similar to those from
photon and electron beams. The lateral profiles are generally quite flat in the central high-dose
region, then fall off rapidly in the penumbral regions, where the penumbra width increases
with depth in the patient. The central-axis depth-dose curve from protons is somewhat similar
to that from electrons, but with a sharper distal falloff. Figures 11 and 12 compare the centralaxis depth-dose curves from several radiation therapy beams, revealing the main dosimetric
properties that are clinically advantageous in many cases, namely, relatively low entrance
dose, large and uniform dose to cover the tumor, and rapid falloff of dose near the end of range
to spare normal tissues. These properties, together with a uniform lateral dose profile and a
sharp lateral penumbral width, allow proton beams to treat a wide variety to tumor sizes and
locations while providing superior sparing of normal tissues in many cases.
Having casually inspected the shape of proton depth-dose curves, we next examine their
structure in greater detail, pointing out nomenclature and the physical processes that govern
the shape of various regions. Figure 13 shows a pristine proton peak along with labels identifying several regions. In order of increasing depth, these are the regions of electronic buildup,
protonic buildup, sub-peak, peak, and distal falloff. The figure also shows several characteristic depths (e.g. the depth zBP at which the peak occurs) and various characteristic lengths (e.g.
the 80%-to-20% distal-falloff length l80-20 and the proximal-80%-to-distal-80% pristine-peak
width).
The anatomic definitions of an SOBP are, in many ways, similar to those of a pristine
Bragg curve, as seen in figure 14. However, there are several unique difficulties in characterizing SOBPs because of their sometimes unusual shape. For example, SOBPs with two or more
R177

Topical Review

Phys. Med. Biol. 60 (2015) R155

Figure 15. Absorbed dose D as a function of depth z in water from a spread-out Bragg

peak (SOBP) (uppermost curve) and its constituent pristine Bragg peaks (lower curves;
for clarity, all but the deepest pristine Bragg peak are only partly drawn). In many
cases, the clinical target volume is larger than the width of a pristine Bragg peak. By
appropriately modulating the proton range and fluence of pristine peaks, the extent of
the high-dose region can be widened to cover the target volume with a uniform dose.

discrete pristine Bragg curves may have multiple dose maxima in the modulated-peak region
(e.g. the ripple shown in figure 15). Because of such problems we introduce a few additional
quantities that are defined only for SOBPs. To a large extent, however, we have defined quantities and terminology that are common to both modulated and pristine Bragg curves.
We have not yet mentioned how MCS affects the shape of the depth–dose curves. In fact,
near the central region of a laterally ‘large’ beam, or more correctly well inside the periphery
of a large beam, there is an equilibrium in which lateral scattering away from the central axis
is exactly compensated by scattering towards it. This effect is described in figure 16, which is
adapted from Koehler and Preston (1972). As the field size shrinks to the dimension of the rms
lateral displacement due to MCS, lateral equilibrium is lost and MCS progressively depletes
the proton fluence and dose along the central axis. Small proton beams have been investigated in several studies, including those by Takada (1996), Moyers et al (1999), Vatnitsky et
al (1999b), Bednarz et al (2010), and Gottschalk (1999), as well as others, especially in the
context of scanned beams and pencil beam dose algorithms.
Here, we use a Cartesian coordinate system with the z axis parallel to and centered about
the proton beam central axis. The x and y axis are mutually orthogonal and perpendicular to
the z axis. The coordinate system origin is located at the front face of the absorber, e.g. the
extended medium in which we consider the absorbed dose distribution.
Pristine Bragg curve: A depth-dose distribution in an absorber irradiated with a monoenergetic or nearly-monoenergetic proton beam. In other words, no device or technique has been
intentionally deployed for modulating the proton fluence or spectral fluence.
Spread-out Bragg curve: A depth-dose distribution in an absorber irradiated with a beam
that has been intentionally modified to increase the axial dimension of the peak region. This is
accomplished by modulating the range and the fluence of the beam. Clinical systems accomplish
this by combining multiple quasi-monoenergetic beams or with a continuously modulated beam.
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Figure 16. (Left) Proton fluence I(0; x) along the beam central axis versus depth x in
water. Curves are shown for beams with circular cross sections and radii of 1 to 4 mm.
Some of the protons are lost because of scattering events that deflect them from the
central axis. This is increasingly observed for small beams and at large depths. (Right)
The corresponding central-axis absorbed-dose curves. Note how the fluence depletion
reduces the absorbed dose at the peak relative to the entrance dose (reproduced with
permission from Preston and Koehler 1998).

Electronic buildup region: A small region near the surface of the absorber where the
proton beam is incident. As discussed in section 2.1, high-energy proton beams liberate delta
rays with sufficient kinetic energy to travel several millimeters in tissue. Under some circumstances, this region exhibits an increase of dose with increasing depth, asymptotically
approaching absorbed dose in the sub-peak region within the depth corresponding to the range
of the most penetrating recoil electron. In some cases, electronic buildup is not observed.
There are several possible reasons for this: the presence of some material just upstream of
the surface (e.g. an immobilization device or a range compensator) may provide partial or
full electronic charged particle equilibrium in the absorber, it may occur in combination with
protonic buildup, it may be masked by changes in the proton energy loss rate near the end of
range, or the wall of a cavity dosimeter may be sufficiently thick to present electronic equilibrium to the dosimeter’s sensitive volume.
Protonic buildup region: A region near the surface of the absorber where the absorbed
dose increases with depth because of the buildup of secondary protons that are attributable to
proton-induced non-elastic nuclear interactions (e.g. 16O(p, xp) reactions). As with electronic
buildup, the protonic buildup may not be observed in some cases, particularly at low incident
proton beam energies.
Sub-peak region: The region extending from the surface of the absorber to the depth
just proximal of the peak. The physical processes involved here are, in decreasing order of
importance, the stopping power’s dependence on the inverse-square of the proton velocity,
the removal of some protons by nuclear reactions, the liberation of secondary particles from
nuclear reactions, and for very small fields, the accumulation of lateral deflections from MCS
leading to lateral protonic disequilibrium and reduction of the proton fluence on the central
axis. The distal extent of the sub-peak region can be calculated from zm- 2σ, where zm is the
depth at the pristine Bragg peak and σ is the width of the peak. The width parameter σ can be
estimated from the incident proton beam spectral fluence and the range straggling accumulated in the absorber, as discussed in section 2.3.
Pristine Bragg peak: The pristine Bragg peak is simply the maximum (or mode) dose near
the end of range, and is located at zBP, which is defined next. The physical processes governing
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the location and/or height of the peak are mainly the proton stopping power and energy straggling, nuclear reactions to a much lesser extent and, for very small fields, MCS.
Pristine Bragg peak depth: The depth near the end of range of the primary protons at
which the protons produce the maximum dose rate, denoted by zBP. Although small proton
beams are not yet widely used, it is helpful to define the location of zBP in a way that is compatible with large and small beams. Figure 16 shows that the maximum dose for beams of diameter
larger than 6 mm is clearly single valued and located near the end of range. For smaller beams,
however, the dose at the peak near the end of range may be less than the dose in the proximal
regions, creating multiple maxima to choose from. Hence, the definition of zBP restricts it to
exist in the region of the R ± 4σ, where sigma is the distal falloff width, thereby preventing possible ambiguities, and makes zBP conceptually independent of the beam cross-sectional area.
Distal falloff region: This region extends from depths greater than that of the pristine
Bragg peak depth, zBP. The width of this region is not restricted. In many practical situations,
however, the distal falloff region can be truncated can be truncated at a depth where the dose
falls below a threshold value, e.g. 1% of the dose at the Bragg peak, D(zBP).
Distal-50% depth: The distalmost depth, denoted by zd50, at which the absorbed dose is
equal to half of the absorbed dose at the pristine Bragg peak depth, or D(zBP)/2. For an SOBP,
it is defined as the distalmost depth at which the absorbed dose is equal to half of the absorbed
dose at the SOBP dose in the modulated peak region. In many cases, the dose in the modulated
peak region varies with depth (perhaps by design), making selection of an absorbed dose valve
in the modulated peak region arbitrary. Since this clearly hinders an unambiguous definition of
zd50, we instead define zd50 for an SOBP as being equal to zb. If the dose in the modulated peak
region varies with depth, zb may have to be determined with numerical methods. Physically,
the value of zb is closely related to the RCSDA value of the mean proton energy corresponding to
the most energetic peak in the SOBP. Definitions for various other distal depths are similarly
defined, e.g. the distal-90% depth zd90 and zd20.
Proximal-50% depth: The second most distal depth, denoted by zp50, at which the absorbed
dose is equal to half of the absorbed dose at the pristine Bragg peak depth, or D(zBP)/2, provided that occurs within the absorber. (For very low-energy pristine Bragg curves, the entrance
dose may be greater than half the peak dose). In such cases, and for SOBPs, it is defined as the
most proximal depth at which the absorbed dose is equal to half of the absorbed dose in the
peak region. Because of problems that are analogous to those described in the zd50 definition
above, zp50 is defined as the location at which the dose is equal to half the value at depth za +
Δ/2, where Δ is the width of the transition from the peak region to the sub-peak region. Δ is
not a critical parameter and it may be estimated as the amount of range straggling at za or it
can be determined from measured Bragg curves. Conceptually, za typically corresponds to the
shallowest location that is expected to receive the maximum dose. Physically, the value of za
is closely related to the RCSDA value of the least energetic pristine peak in the SOBP curve (or
the only peak in the Bragg curve for a pristine peak). In many cases, particularly for SOBPs
with large modulated-peak regions, the absorbed dose throughout the sub-peak region exceeds
50% of the value at za + Δ, in which case proximal 50% depth is undefined. In such cases,
proximal depths at higher dose percentages, such as zp95 and zp90, may be used. If the Bragg
peak occurs at zero depth, as is commonly the case for treating superficial tumors, one may
simply use zp100 = 0.
80%-to-20% distal-falloff length: The distance between the distal-80% and distal-20%
depths, denoted by ld80-d20. Other distal-falloff lengths are similarly defined, e.g. the 90%-to10% distal-falloff length ld90-d10.
Proximal-80%-to-distal-80% pristine-peak width: The distance between the proximal-80% depth and the distal-80% depth, denoted by lpristine_d80-p80, where the proximal-80%
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and distal-80% depths are defined analogously to the distal-50% depth, zd50, already defined.
Other pristine peak widths are similarly defined, e.g. the 80%-to-80% pristine peak width. In
cases where the Bragg curve does not include a proximal 90 dose point, the methods described
in ‘Proximal-50% depth’ may be used.
Proximal-80%-to-distal-80% modulated peak width: The width of the modulated peak
region is defined as lmod_d80-p80 = zd80 − zp80. In cases where the Bragg curve does not include
a proximal 80% dose point, the methods described in ‘Proximal-50% depth’ may be used.
Modulated-peak region: The region extending from za to zb. In general, the values of za
and zb are most reliably determined using iterative numerical fitting methods. Conceptually,
they are closely related to the proton ranges of the most and least penetrating pristine peaks
in the SOBP.
These definitions may initially appear pedantic and overly precise for a conceptual understanding of proton Bragg curves. However, experience has shown that these definitions
facilitate quantitative analysis and reporting of the characteristics of a wide variety of Bragg
peaks in clinical and research settings. The definitions were developed from experience in
manual and algorithmic analyses of measured clinical pristine and spread-out Bragg curves
(Newhauser 2001a, 2001b, Newhauser et al 2002a, 2002b) and for developing and commissioning proton dose algorithms for treatment planning purposes (Koch and Newhauser 2005
2010, Newhauser et al 2007b). Finally, we note that in some clinical situations, the practicing medical physicist may need to define and use additional parameters, e.g. zp98 and zd98, as
appropriate to a particular clinical situation or protocol. Regardless of the particular parameters chosen, it is difficult to overstate the paramount importance of using the parameters in a
consistent way and being clear about their meaning when reporting results.
3.3. Model of pristine Bragg curves

In the preceding sections, we described all the major physical processes that govern the shape
of proton dose distributions. Pristine Bragg curves may be calculated using a wide variety of
techniques, from look-up tables of measured data to Monte Carlo simulations to analytical
models. In the early days of proton therapy, indeed through the 1990s, dose algorithms in most
proton treatment planning systems included very few, if any, physical models in their dose calculation algorithms. However, in the last 15 years of so, much progress has been made in modeling proton dose distributions with increasing physical completeness, realism, and accuracy.
In this section, we review a method to calculate a pristine Bragg curve using a physics-based
analytical model. For brevity, we present only one model, a model that describes many of the
important physical processes, is computationally straightforward and fast, and is of considerable practical value in a clinical proton setting.
Bortfeld (1997) proposed an analytical equation to calculate the Bragg curve for proton
energies between 10 and 200 MeV, as follows:
D(z ) = Φ0

2
⎤
⎛β
e−ζ /4σ 1/ pΓ (1 / p) ⎡ 1
ε ⎞
⎢ D−1/ p(−ζ ) + ⎜ + γβ +
⎟ D−1/ p − 1(−ζ ) ⎥ ,
 1/ p
R0 ⎠
⎝p
2π ρpα (1 + βR0 ) ⎣ σ
⎦

(36)

where D(z) is the depth dose, z is the depth, Φ0 is the primary fluence, R0 is the range of
the proton beam, σ is the standard deviation of the Gaussian distribution of the proton depth,
ζ = (R0 − z)/σ, α and p are material-dependent constants (defined in equation (2)), ε is the
fraction of low-energy proton fluence to total proton fluence, Γ(x) is the gamma function, and
Dy(x) is the parabolic cylinder function. Very good agreement is found between measured and
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Figure 17. Absorbed dose D as a function of depth z in water from unmodulated
(pristine) proton Bragg peaks produced by a broad proton beam with an initial energy
of up to 235 MeV. With increasing depth, the accumulation of range straggling tends to
broaden the peak. Beams that are more penetrating therefore have larger distal falloff
distances.

calculated curves, and this approach has been used for the analysis and characterization of clinical proton beams (figure 17) (Newhauser et al 2002b) and for treatment planning dose calculations (Szymanowski and Oelfke 2003, Soukup et al 2005, Rethfeldt et al 2006, Li et al 2008).
3.4. Model of spread-out Bragg curves

Spread-out Bragg curves may be designed by combining multiple pristine Bragg curves. This
approach was described in Wilson’s seminal paper and its implementation was described by
Koehler et al (1977). Figure 15 plots several pristine Bragg curves and their resultant sum,
which was similar to the SOBPs used at Harvard from the early 1970s onwards. The fluence is
also modulated, which can be seen in the same figure as variations in the relative peak dose of
each pristine Bragg curve. The range is typically modulated in steps that are small compared
with the width of the Bragg peak, so that the SOBP contains little or no ripple. The modulation step size may be fixed or variable; generally the smallest step increments are needed for
the deepest peaks, e.g. the amplitude of the ripple decreases with depth because an increasing
fraction of dose is from the sub-peak region of the Bragg curves. Figure 18 plots several typical clinical SOBPs from a contemporary proton therapy system.
SOBPs can also be modeled with analytical methods. Bortfeld and Schlegel (1996) proposed a model of the form
⎧3
2zˆ − 1
1 + zˆ 2
3
3
⎪ +
arctan
ln
−
2
⎪4
2π
4π 1 − zˆ + zˆ
3
D (z ) = ⎨

1
⎪
⎪0
⎩

where the dimensionless depth z ̂ is given by
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Figure 18. Absorbed dose D as a function of depth z in water from various SOBPs

from the Northeast Proton Therapy Center (NPTC) nozzle. Open-beam central-axis
depth-dose curves are plotted for each of the eight range modulator wheel tracks. The
experimental values (open circles) are from charge measurements with an air-filled
ionization chamber, and the model fits are shown with solid lines. Each range modulation
track was designed to work over an interval of proton energies. The flat modulated-peak
region was achieved by modulating the proton-beam current synchronously with the
modulator wheel rotation.

z ̂ =

3

za − z
,
z b − za

(38)

and where za and zb denote the depths of the proximal and distal extents of the SOBP (see
preceding section for details of their definitions) and z is the depth in water. The model was
derived with several simplifying assumptions and approximations that limit its ability to predict real SOBPs. In particular, the proton energy loss rate is based on the CSDA (i.e. energy
straggling is neglected) and the converted energy per unit mass approximation (where the proton energy loss and the absorbed dose in the water are assumed proportional), and non-elastic
interactions of the protons with the absorber nuclei were not considered. Consequently, it does
not reproduce real SOBPs well.
To attain a more realistic model, one of us (WN) introduced terms for the finite distalfalloff distance associated with range straggling, protonic buildup effects, arbitrary slope of
the modulated-peak region, and a term for the ripple in the modulated peak. In addition, the
piecewise use of the function for various regions was modified to allow for a transition region
between the sub-peak and modulated-peak regions, which eliminated a pronounced discontinuity there. With these additional terms and modified regions, the model becomes
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where z ̂ is defined as before, c0 is a proportionality constant, Λ takes into account the dependence on the dose due to inverse-square-law reductions in the proton fluence, βBU is the secondary-particle buildup term, c1 through c5 are coefficients that influence the shape of the
sub-peak region, and m and b are the slope and intercept the of the modulated-peak region,
respectively. The ripple in the modulated-peak region is described by the term Y, e.g. an unerdamped harmonic oscillator. The distal falloff term is denoted by γ and is modeled with a
cumulative normal PDF. The transition region is centered about za and is of width Δ, which is
a non-critical parameter that can be estimated from the amount of range straggling expected
at depth za (see previous section for detailed definition) or it may be empirically deduced from
measured Bragg curves. The extended model agrees well with measured SOBPs, several of
which are shown in figure 18. This work was previously unpublished.
3.5. Analytical transport of therapeutic proton beams

Analytical models to predict therapeutic radiation are generally simple, fast, and accurate.
Early treatment planning systems, many of which were still in use in the 1990s, used dose
algorithms that looked up measured profiles of absorbed dose and/or used empirical formulas. Over the last 15 years, advances in our understanding of proton therapy physics, as well
as huge gains in computer speed and memory capacity, have spurred the development and
clinical use of increasingly realistic and complete physical models to predict absorbed dose
in patients.
The basic approach underlying most analytical dose algorithms is that the proton beam’s
energy loss and lateral scattering may be modeled independently from one another. The physical basis for this assumption lies in the principle of conservation of momentum and energy.
Lateral scattering, which is predominantly caused by MCS, occurs at small angles (see section 2.4). Hence, the energy loss associated with the vast majority of these small scattering events is negligible. Conversely, the predominant proton energy-loss mechanism, namely
inelastic Coulomb interactions with atomic electrons, only negligibly deflects the protons
because the proton rest mass is 1832 times greater than that of an electron (see section 2.1).
Consequently, for an excellent approximation, the 3D distribution of absorbed dose in a phantom or patient may be cast in the form of
D (x, y, z ) = D (z ) × OAR (x, y, z ) ,

(40)

where x and y are lateral coordinates, z is the depth coordinate along the beam axis, D(z) is the
large-field Bragg curve (i.e. with lateral protonic equilibrium, described in section 3.2), and
OAR(x, y, z) is a term that takes into account the lateral properties of the dose distribution.
Broad beam algorithms use equation (40) with simple ray-casting techniques (Siddon 1985) to
determine the energy loss and range along each ray. Similarly, to determine the lateral extent
of the therapeutic field, the rays are terminated in target-shaped final collimators by approximating them as black-body absorbers (Hong et al 1996). Carefully designed broad beam algorithms are simple, fast, and accurate in media that are of relatively uniform mass density and
material composition. Recently, Koch and Newhauser (2010) developed an analytical broad
beam algorithm of the form
N
D (x , y , z )
DDi(z eff ) SAF RMW⎛ SSD + z eff ⎞2
⎜
⎟ OARi ⋅ Γi ,
=∑
ωi ωi

⎝ SSD + z ⎠
MU
MU
i=1

(41)

where N is the number of range modulation steps, ωSAF is the scatter and attenuation fluence weighting factor, ωRMW is the range modulator wheel (RMW) fluence weighting factor,
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Figure 19. (Upper) Geometric model of proton therapy unit and the voxelized phantom
oriented for the superior spinal proton field. The beam delivery system includes a
vacuum window (A), a beam profile monitor (B), a range modulator wheel (C), a second
scatterer (D), a range shifter assembly (E), backup and primary monitors (F), the snout
(G), the range compensator (H), the treatment couch (I), and the patient (J) (reproduced
with permission from Zhang et al 2013a). (Lower) Simulated proton transport through
the proton therapy unit and the patient.

OAR is off-axis ratio, and Γ is collimation modifier. This algorithm explicitly takes into
account edge-scattered protons and range straggling, predicts absolute dose per monitor unit
(D / MU) values, and provides excellent agreement with measurements in homogeneous
media, e.g. for ocular treatments. In highly heterogeneous media, however, the dose at some
locations may depend strongly on the material properties of the heterogeneities in the overlying tissue, and therefore the approach of casting a single ray does not, in general, provide
sufficient dosimetric accuracy.
To improve the dosimetric accuracy in heterogeneous media, the dose may be calculated
at a point as the superposition of multiple pencil beams. A pencil beam is, in essence, a mathematical construct that has no exact and direct analogy in the physical world, but it is resembles a beam of infinitesimally small lateral size. By superposing enough pencil beams, the
physical dose distribution can be modeled. Fortunately, as we shall see, many of the physical
principles and algorithmic aspects from the broad beam approach are directly applicable to
the pencil beam algorithm.
Hogstrom et al (1981) originally proposed a pencil beam algorithm for electron therapy.
Basically, an ion beam is divided into a number of finite pencil beams and the dose distribution
of each pencil beam is described by the multiplication of a central-axis term and an off-axis
term. The final relative absorbed dose to any point in the patient (Dp(x, y, z)) is the summation
of the dose contributions from all the pencil beams:
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Dp(x, y, z ) =

⎛

⎞2

+ z eff
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× exp ⎜−
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⎝
⎠

1
2
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(z )

(42)

where S(x′, y′) is the relative intensity of the pencil beam at x′, y′, PDD(z) is the centralaxis percentage depth dose, SSD is the source-to-surface distance, zeff is the effective depth
2
of the point, and σtot
describes the final lateral distribution of a pencil beam by taking into
account the MCS contributions from each beam-modifying device and from the patient. Many
other groups have subsequently adapted and extended this concept for application in proton
therapy (Petti 1992, Hong et al 1996, Schaffner et al 1999, Szymanowski and Oelfke 2002,
Ciangaru et al 2005, Schaffner 2008, Westerly et al 2013). Contemporary proton pencil beam
algorithms provide excellent accuracy (Newhauser et al 2007b), especially in homogeneous
media, superior to that of broad beam algorithms in heterogeneous media. The improvement
in accuracy comes mostly at the cost of greater computation times. Because of approximations
in the pencil beam algorithm, it may not provide sufficient accuracy in extremely heterogeneous media, at material and/or density interfaces, or in other complex situations.
Currently, most proton therapy clinics utilize commercial treatment planning systems that
contain pencil beam algorithms for calculation of therapeutic dose distributions. Computation
speeds are generally sufficiently fast for most routine planning.
3.6. Monte Carlo transport of therapeutic proton beams

Monte Carlo transport technique has been used increasingly in radiation therapy (Seco and
Verhaegen 2013). It is more accurate than analytical models in that it takes into account the
physical processes during particle transport. The most commonly used general purpose Monte
Carlo codes for proton therapy research are MCNPX (Pelowitz 2011), Geant 4 (Agostinelli
et al 2003), and FLUKA (Ferrari et al 2005). Several groups have developed special purpose
Monte Carlo codes, e.g. a treatment planning dose engine (Tourovsky et al 2005, Yepes et
al 2009a), typically with faster computation speed but fewer features than general purpose
codes. Here we focus mainly on applications that use the MCNPX code because it is representative of most general purpose codes, we are familiar with it, and constraints on journal space
do not allow discussion of all codes.
The main components of a Monte Carlo simulation model are a source of protons, a treatment head, and a patient or phantom (figure 19). The proton source is typically taken as being
incident on the treatment head (beamline transport is not usually simulated), where the source
parameters are deduced from dose profile measurements (Newhauser et al 2005) or taken
from other beam properties, e.g. from the manufacturer (Newhauser et al 2007b). The model
of a treatment head typically includes all major mechanical components, e.g. a vacuum window, a beam profile monitor, a range modulator wheel, a second scatterer, shielding plates, a
range shifter assembly, backup and primary monitors, the snout and the brass collimator, and
a patient-specific range compensator (Zheng et al 2007b, Perez-Andujar et al 2009). Models
of scanned beams include magnetic fields and transport the proton beam deflection (Peterson
et al 2009, Dowdell et al 2012), or the proton source may be pointed, e.g. using the ‘thin lens’
approximation to increase computation speed (Lee 2004). The patient may be represented
in voxels whose material composition and mass density are deduced from 3D CT images of
the patient (Taddei et al 2009). The matrix of Hounsfield unit values in these voxels may be
converted into corresponding matrices of material composition and mass density values based
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on a tri-linear calibration curve (Newhauser et al 2008a). A simulation capability to accommodate time-dependent geometry was reported by Paganetti et al (2005).
Some useful applications of the Monte Carlo method are described here:
(a) Alternative or complimentary source of dosimetric data for developing, configuring, and
validating analytical dose algorithms in clinical treatment planning systems. At least two
studies revealed that, after a significant development effort, a Monte Carlo model of a
proton therapy apparatus is sufficiently accurate and fast for prospective commissioning
of an ocular treatment planning system (Koch and Newhauser 2005, Newhauser et al
2005) and a large-field treatment planning system (Newhauser et al 2007b). This prospective capability reduced the time required for preclinical work by several months, resulting
in substantial cost savings. Studies about scanning proton beam configuration have also
been reported (Tourovsky et al 2005, Sawakuchi et al 2010, Dowdell et al 2012).
(b) Alternative dose engine to calculate absorbed dose in phantoms or patient. In clinical
practice, there frequently arise challenging cases where the accuracy of analytical models
is unknown or suspected to be insufficient. In many such cases, measurements are not
possible or practical, e.g. intracranial in vivo range verification. Multiple groups have
developed Monte Carlo treatment planning engines (Tourovsky et al 2005, Newhauser
et al 2008b, Perl et al 2012, Mairani et al 2013) based on various Monte Carlo codes,
independently proving the technical feasibility of this approach. The physics of general
purpose Monte Carlo codes for this purpose has been exhaustively validated against
benchmark measurements in therapeutic proton beam data (Polf 2007, Kimstrand et al
2008, Titt et al 2008a, Randeniya et al 2009). Just 10 years ago, the slow execution
times, memory constraints, unknown accuracy, and unknown technical feasibility of a
full-blown Monte Carlo engine were serious research challenges. Today, the only major
remaining obstacle to routine use of Monte Carlo engines for treatment planning is their
slow execution times. For example, a proton craniospinal treatment simulation took more
than 104 CPU hours (Taddei et al 2009). Encouragingly, however, algorithmic improvements have increased speeds dramatically; Zhang et al (2013a) found that using lattice
tally in MCNPX can speed up dose simulations by one order of magnitude compared to
mesh tally, especially for dose reconstructions involving large numbers of voxels. The
physics of the radiation transport are identical for the lattice and mesh tallies, i.e. there
was no loss of accuracy. Yepes et al (2009b) recently reported on a fast dose calculator,
a Monte Carlo track-repeating algorithm that uses a database of pre-computed proton
trajectories in water and applies these trajectories to heterogeneous media by scaling
the proton range and scattering angles. This approach reduced the computation time for
dose reconstruction in voxelized patient geometry by more than two orders of magnitude
compared to MCNPX and GEANT4 (Yepes et al 2009a, 2010a). The use of low-cost
alternative parallel computer architectures also appears promising, including the use
of graphics processing units (Yepes et al 2010b, Jia et al 2012) and grid technologies
(Vadapalli et al 2011).
(c) Assessment of beam perturbation due to objects implanted in patients and development
of mitigating strategies. The proportion of cancer patients with implanted devices is probably less than 10%, but it is increasing because of the aging of the population, increasing
life expectancies, and increasing use of implanted devices. Examples include cardiac
pacemakers, defibrillators, fiducial markers for radiotherapy localization, permanent
radioactive seed implants, stents, prostheses, surgical reconstructive devices, and foreign
bodies such as gunshot and shrapnel. Analytical dose algorithms in contemporary clinical
treatment planning systems lack the capability to reliably assess dose perturbations from
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most implants. Several studies reported that implanted metallic fiducials can cause dose
shadows that may compromise local tumor control for certain diseases, e.g. prostate carcinoma and uveal melanoma (Newhauser et al 2007a, 2007c, Giebeler et al 2009, Cheung
et al 2010, Huang et al 2011, Matsuura et al 2012, Zhang et al 2012, Carnicer et al 2013).
(d) Investigation of characteristics of therapeutic beams and beamlines. For example, edgescattered protons can degrade the dose distribution, and the effect is difficult to model
with current analytical models. Accurate predictions of D / MU require taking into
account the dose from protons scattered from the edge of the patient-specific collimator,
particularly for small field sizes and large depths (Titt et al 2008b). Currently available
spot scanning system only offer few options for adjusting beam spot properties like lateral
and longitudinal size, and Monte Carlo simulations was used to optimize scanned beam
spot (Titt et al 2010).
Because the Monte Carlo simulation technique is inherently general, it can be applied to
virtually any problem involving the transport of protons or secondary radiation. Space constraints prevent us from reviewing more than a few illustrative examples. In later sections we
briefly mention roles for Monte Carlo methods in research on stray radiation exposures to
patients (section 5) and shielding barriers to protect staff (section 6).
4. Therapeutic absorbed dose determination
4.1. Reference dosimetry

By reference dosimetry, we mean the determination of absorbed dose in a manner that allows
it to be directly related or referred to an accurate and uniform standard of absorbed dose.
Clinical reference dosimetry comprises the measurement of absorbed dose in a clinic, which
is related to the absorbed dose at a primary or secondary standards laboratory. This approach
ensures that clinical reference dosimetry is accurate and uniform across participating institutions. Typically, clinical reference dosimetry is established by first calibrating a clinic’s
dosimeter at a standards laboratory, then ‘transferring’ the calibration to the clinic’s treatment
beams. To minimize systematic errors introduced by this transfer process, both irradiations
are made with the same dosimeter and under identical (or very similar) ‘reference conditions’. Therefore, reference conditions must be reproducible and clinically relevant. However,
national or international calibration laboratories do not yet produce proton calibration beams
of relevance to proton therapy (presumably due to prohibitively high costs, low demand, and
limited resources). Because of this limitation, the proton therapy community developed alternative methods for proton reference dosimetry.
For many decades, the reference fields for calibrating proton dosimeters were characterized
using a Faraday cup (Verhey et al 1979) to measure the proton fluence in air. Today, most proton therapy institutions implement reference proton dosimetry utilizing an ionization chamber
technique to measure the absorbed dose to water. With the latter technique, an ionization
chamber is calibrated using reference conditions for photon therapy (i.e. 60Co radiation fields
that are widely available at calibration laboratories) and a correction factor is applied that corrects the differences in the chamber’s response to 60Co and proton beams. When implemented
properly, the techniques agree within uncertainties (Newhauser et al 2002a, 2002b).
Several advisory bodies have published dosimetry protocols for reference dosimetry, such
as the American Association of Physicists in Medicine (AAPM 1986), the European Clinical
Heavy Particle Dosimetry Group (ECHED) (Vynckier et al 1991, 1994), the International
Commission on Radiation Units and Measurements (ICRU 1998, 2007), and the International
Atomic Energy Agency (IAEA 2000). Vatnitsky et al (1999a) performed an international
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proton dosimetry inter-comparison based on the ICRU Report 59 protocol (ICRU 1998) and
reported that absorbed dose to water can be delivered within 3%.
4.2. Patient field–specific dosimetry

The determination of absolute absorbed dose per monitor unit for each patient and treatment
field, denoted by D / MU, rests upon the foundation of reference dosimetry. Recall that reference dosimetry is performed under simple and reproducible conditions, e.g. using a dosimeter in a water-box phantom. In contrast, dosimetry in a patient should take into account the
full complexity of a patient’s anatomy, e.g. irregular surface shapes, heterogeneous elemental
composition and mass density, and treatment field size and shape. These additional complexities call for a conceptual framework and measurement techniques for performing routine
D / MU determinations for patient treatment fields.
For several decades, D / MU values for passively scattered treatment beams were typically
measured at depth in a water-box phantom the range compensator present. However, a systematic study by Fontenot et al (2007) that measuring D / MU without the range compensator
present provided more reliable results because use of the range compensator increased the
severity of dose gradients near the calibration point and this resulted in larger overall uncertainties in D / MU. It is not known if this finding holds for special cases, e.g. small diameter
treatment beams, large air gaps, and moving targets. In many practical situations, it is convenient or necessary to predict the absolute dose in a patient based on the corresponding dose
under reference conditions (e.g. a water phantom). Because an exact theoretical approach
is not possible, all approaches have utilized approximate methods, numerical calculations,
measurements, or a combination of these. On the basis of previous studies, Newhauser et al
(2014a, 2014b) reported the following method to calculate proton dose in a patient (D / MU)p:
⎛ D ⎞
⎛ D ⎞
⎜
⎟ = ⎜
⎟ ·F
⎝ MU ⎠ p ⎝ MU ⎠w CSPS

⎛ D ⎞ref
⎟
=⎜
·F ·F ·F
·F
·F ·F ·F ,
⎝ MU ⎠w OF RS SOBP InvSq FS ColS CSPS

(43)

where (D / MU)w is the D / MU in a water phantom under patient-specific field conditions;
FCSPS is the compensator scatter and patient scatter factor, which takes into account differences in the scattering and attenuation of the patient and range compensator together relative
to that of water and no range compensator; (D / MU)wref is the D / MU in a water phantom
under reference conditions and is typically 1 cGy/MU; FOF corrects for proton beam energy
spectrum relative to the reference condition; FRS corrects for range shifter effects; FSOBP corrects for SOBP effects relative to the reference field; FInvSq corrects for beam divergence
relative to the reference condition; FFS corrects for field size effect; and FColS corrects for
differences in scatter from the reference aperture (e.g. 10 cm × 10 cm) to the patient-specific
aperture. They found that for prostate treatment fields, uncertainty in FCSPS, which is the
least well understood factor, was clinically acceptable for prostate treatment (Newhauser et al
2014b). In a companion study, the same group reported the variability in FCSPS was clinically
significant for some lung treatment fields (Newhauser et al 2014a).
For scanning proton beams, it is important to calibrate individual spot beams because
patient specific collimating apertures or range compensators are not typically used in the beam
line. First the number of protons per MU for each beam energy is calibrated by Faraday-cup
measurements or Monte Carlo simulations. Then, either physical model or Monte Carlo simulation can be used to calculate absolute dose normalized to the number of incident protons. A
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simple nuclear halo model was developed at Paul Scherrer Institute (PSI) (Pedroni et al 2005)
to include secondary dose around the primary pencil beam and can predict precisely the dose
directly from treatment planning without renormalization measurements.
In addition to the physical effects already discussed above, there are many additional
effects that contribute to the uncertainty in D / MU that arise from imperfections in anatomic
images used for treatment planning, organ motion, and in the case of scanned beams, the
interplay of organ motion and the moving beam, etc. Such uncertainties may depend strongly
on anatomical site, approximations utilized by the treatment planning system, beam delivery
system, and experimenter’s skill. Ideally, clinical treatment planning systems would provide
accurate estimates of (D / MU)wref and (D / MU)p with known and small uncertainties, methods
for determining and reporting (D / MU)p would be standardized, and secondary methods (e.g.
hand calculations similar to equation (43) or fast Monte Carlo simulations) would be available
to independently verify (D / MU)p values determined with the primary method. In principal,
there appears to be an adequate knowledge of basic proton interaction physics and transport
physics to reach or approach these clinical ideals. In addition, recent research studies report
encouraging results for a variety of special cases, e.g. for a particular treatment technique,
treatment planning system, or treatment delivery systems. As mentioned in section 3.5, Koch
and Newhauser (2010) developed an analytical broad beam algorithm to predict absolute dose
per monitor unit (D / MU) values with good accuracy in water for ocular proton treatments,
but the ability to predict D / MU in the heterogeneous patient body still needs improvement.
To date, the methods for determining (D / MU)p in the literature have not yet been validated
for general application and they have not been standardized.
5. Stray radiation
As with other forms of external-beam radiation therapies, proton beams unavoidably produce
stray radiation that impinges on the patient’s entire body (figure 20). In the 1990s, very little
was known about the exposure of patients to stray radiation produced by therapeutic proton
beams. By the mid 2000s, concerns about stray radiation had become a matter of considerable
speculation and controversy, particularly regarding the suitability of proton beams for treating
children with cancer because of concerns about the risks from stray neutron exposures (Hall
2006, Brenner and Hall 2008). By the late 2000s, research on stray radiation exposures from
proton and other radiation therapies had intensified and some questions have been partially
or fully answered. However, many questions remain open. In this section, we review selected
developments and discuss a few open questions.
In a study using Monte Carlo simulations, Agosteo et al (1998) reported that neutron exposures were the principal concern among the various types of stray radiation from proton therapy. Comprehensive measurements in clinical proton therapy beams were reported by Yan et
al (2002), including neutron spectral fluences and dose-equivalent data for large-field, radiosurgery, and ocular beamlines. That study included measurements of neutron energy spectra
and neutron dose-equivalent values. Several other groups have measured neutron exposures,
including Roy and Sandison (2004), Tayama et al (2006), Mesoloras et al (2006), Schneider
et al (2002) and Wroe et al (2007). The early measurements were important because they suggested that the neutron exposures, while generally small in comparison to therapeutic doses,
should not be neglected.
Several groups developed neutron dose reconstruction systems based on general purpose
Monte Carlo codes for a wide variety of clinical proton beamlines (Siebers 2000, Jiang et al
2005, Polf and Newhauser 2005, Fontenot et al 2005b, Newhauser et al 2007b, 2008b, Zheng
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Figure 20. Schematic diagram of proton beam irradiation of the spine. There are several
distinct sources of radiation exposure, including therapeutic protons (red), stray neutrons
emanating from the treatment apparatus (blue), and neutrons produced by therapeutic
proton radiation inside the body. A small-diameter beam of protons enters the treatment
apparatus, which spreads the beam to a clinically useful size and collimates it to spare
healthy tissues. The stray neutron is created by proton-induced nuclear reactions inside
the treatment unit, some of which leak out and irradiate the patient. The stray radiation
exposures provide no therapeutic benefit but increase the predicted risk that a patient
will develop a radiogenic side effect, such as a second cancer, later in life (reproduced
with permission from Newhauser and Durante 2011).

et al 2007b, Moyers et al 2008). A wide variety of simulation approaches have been used, with
varying degrees of clinical realism, assumptions, and approximation, and not surprisingly,
rather disparate results. Some of the literature on measurements and simulations of neutron
exposures was reviewed in NCRP Report 170 (2011). In the remainder of this section, we
emphasize progress subsequent to that report.
Research methods of relevance to stray radiation estimation have progressed dramatically
since Agosteo et al (1998) published their pioneering study using Monte Carlo simulation
to study neutron fluence and dose in air or in a simple water box phantom. One key advance
was the validation of Monte Carlo predictions against benchmark neutron measurements, for
example the studies of Tayama et al (2006), Fontenot et al (2005a), and Polf et al (2005).
High-performance computing techniques, such as using massively parallel computing clusters, allows fast simulations of whole-body dose reconstructions involving complex treatment techniques, e.g. craniospinal irradiation (CSI) (Newhauser et al 2009, Taddei et al 2009
2010b, Perez-Andujar et al 2013a, Zhang et al 2013c), which is widely considered one of the
most challenging treatments to simulate. Another key advance was increasing the level of realism in modeling anatomy. Methods have progressed in 1998 from simple water-box phantoms
to stylized anthropomorphic phantoms to generic voxelized phantoms in the mid 2000s to
patient-specific personalized phantoms by the late 2000s (i.e. by retrospectively using treatment planning CT scans). In fact, this year a study was completed comprising a 17-patient
in silico clinical trial comparing proton CSI and photon CSI, according to the contemporary
standards of care, including full Monte Carlo simulations of stray and therapeutic exposures
(Zhang et al 2014).
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Another research result of considerable clinical relevance is that it is possible and indeed
feasible to dramatically reduce exposures from stray neutrons that leak out of the treatment
apparatus. For example, Taddei et al (2008) found that modest modifications of the treatment
unit (adding shields near the patient, using a tungsten-alloy collimator, and adding an upstream
collimator near the range shifter assembly) substantially reduced the neutron dose (by 66%)
for patients receiving passively scattered proton therapy for prostate cancer. Similarly, Brenner
et al (2009) investigated various pre-collimator/collimator combinations with different geometries and materials and concluded that an optimized design can be achieved to significantly
reduce the stray neutron dose.
Despite the rapid growth of research on stray neutron radiation exposures to patients, the
literature is mainly limited to a few case studies and anatomical sites. In general, the knowledge of stray radiation from proton therapy is still largely incomplete. The gaps in knowledge
received considerable attention following the cautionary paper by Hall (2006), who suggested
that the use of advanced radiotherapy modalities like proton therapy may not be justified
because of incomplete knowledge of stray neutron exposures and second cancer induction.
From subsequent studies, a coherent picture is gradually emerging: second cancer risk following proton therapy is lower than that after photon therapy, the risk differential depends
strongly on anatomic site and other host and treatment factors, the risk posed by stray radiation is small but not negligible, and the largest reductions in risk are achieved by using scattered- or scanned-proton beams instead of photon beams. Furthermore, the majority of risk of
radiogenic second cancer is from in-field radiation, not out-of-field radiation. Consequently,
the difference in predicted total risk (from both in-field and out-of-field radiation) from
scanned versus scattered proton treatments is small and clinically negligible. At the risk of
oversimplification, the theoretical risk advantage of proton therapy derives mainly from its
ability to spare healthy tissues that are distal and lateral to the target volume. With judicious
treatment techniques (e.g. beam orientations, location of field junctions, etc.), it is possible in
many cases to utilize the rapid distal and lateral dose falloff of proton beams to reduce the dose
to sensitive organs and tissues to below levels achievable with technologically comparable
photon treatments.
It is worth underscoring that our knowledge and understanding of this topic in incomplete
and likely to evolve substantially in the future. Current dose and risk assessments are mostly
based on standard-of-care treatment plans, i.e. using clinical planning and research systems
that do not attempt to algorithmically minimize risk of radiation side effects. As clinical treatment planning systems are incrementally extended with these capabilities, the standards of
care for proton and photon therapies will continue to evolve. This evolution will likely render
our current understanding of radiation risks obsolete.
5.1. Monte Carlo simulations

During the transport of proton beams through the treatment unit to the patient, not only is
therapeutic radiation deposited in the patient but also stray radiation is generated because of
nuclear interactions (as explained in section 2.4). In proton therapy, secondary neutrons are
dominant among this stray radiation and are a major concern (Agosteo et al 1998, Fontenot
et al 2008). Estimation of stray neutron dose can be challenging and time consuming, and the
variations in measurement or calculation results can be large (Xu et al 2008).
The inherent accuracy of Monte Carlo simulation makes it an irreplaceable tool for stray
neutron dose estimation, and indeed this technique has been used by many investigators
studying stray neutrons generated during proton therapy (Agosteo et al 1998, Jiang et al
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2005, Zheng et al 2007a, 2008, Moyers et al 2008, Zacharatou Jarlskog and Paganetti 2008,
Newhauser et al 2009, Taddei et al 2009, 2010a, 2010b, Athar et al 2010, Zhang et al 2013b).
Using MCNPX, both external neutrons (neutrons generated in the treatment unit) and internal
neutrons (neutrons generated within the patient’s body) can be accurately simulated (Taddei
et al 2009).
Polf and Newhauser (2005) found that neutron dose equivalent per therapeutic absorbed
dose (H / D) at different locations around a passively scattered proton therapy unit increased
with increasing range modulation and that the major source of neutrons shifted from the final
collimator to the range modulation wheel. Zheng et al (2007a, 2007b) reported that H / D
generally increased with decreasing collimating aperture size, increasing proton beam energy,
and increasing SOBP width, while it decreased with snout distance from the isocenter and
increasing distance from the treatment unit. More than 50% of the neutron dose at all locations
was from neutrons with energies higher than 10 MeV. Zheng et al (2008) also reported that
neutron spectral fluence contained two pronounced peaks, a low-energy peak around 1 MeV
and a high-energy peak that ranged from around 10 MeV up to the proton energy. The mean
neutron radiation weighting factors varied only slightly, from 8.8 to 10.3, with proton energy
and location for a closed-aperture configuration.
5.2. Analytical model

Because of the complexity associated with Monte Carlo simulation and measurement, a simple analytical model to predict stray neutron dose in proton therapy is desirable. Zheng et al
(2007b) proposed an exponential decay model to predict H / D in air with good accuracy. This
largely empirical model was extended by Zhang et al (2010a) to predict H / D both in air and
in the patient’s body by taking into account off-axis effect, phantom attenuation effect, and
low/high energy peaks observed in neutron spectral fluence. Perez-Andujar et al (2013b) subsequently enhanced the model by replacing empirical components with physics-based components, obtaining
(H / D )d = (H / D )iso (d / d iso )−p
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where (H / D)iso is the neutron equivalent dose per therapeutic absorbed dose at isocenter. C1,
C2, C3, and C4 apportion the H / D contributions from intranuclear cascade, evaporation, epithermal, and thermal neutrons, respectively. (d/diso)−p represents the power law that governs
the neutron dose falloff as a function of distance from the effective neutron source, which is
independent of the proton beam energy, d represents the distance from the neutron source in
the treatment nozzle to the detecting volume and diso is the distance from the neutron source
to isocenter. α1, α2, α3, and α4 denote the attenuation coefficients of intranuclear cascade,
′ is the distance from the phanevaporation, epithermal, and thermal neutrons, respectively. d iso
tom surface to the isocenter, and d′ is the distance from the phantom surface to the detecting
volumes. The lateral distribution of neutrons is governed by σ1 for intranuclear cascade, σ2 for
evaporation, σ3 for epithermal, and σ4 for thermal neutrons. z is the longitudinal coordinate for
the neutron dose receptor and is used to scale the width parameters.
The accuracy of this model is comparable to the accuracy of typical Monte Carlo simulations or measurements of neutron dose (figure 21). Taddei et al (2013) modified the model
reported by Zhang et al (2010a) and used a simplified double-Gaussian model to calculation
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Figure 21. Results from Monte Carlo simulations and analytical model predictions of

equivalent per therapeutic dose (H / D) for proton beams with various energies in the
water phantom as a function of vertical depth (a) and lateral distance (b) (reproduced
with permission from Perez-Andujar et al 2013b).
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out-of-field dose in photon therapy and they also had good agreement between measurement
data and model-based values.
With additional research and development on stray dose algorithms, it will be possible to
implement them in treatment planning systems and use them for routine clinical purposes.
6. Shielding design
In this section, we will briefly review the design of shielding to protect humans from stray
radiation. In particular, we will focus on the bulk shielding barriers (e.g. walls, ceilings) and
mazes. Bulk shielding is an extremely important aspect of facility design because proton
therapy equipment is capable of producing lethal levels of stray radiation. In addition, bulk
shielding intrudes on space available for equipment and personnel and it is expensive. In many
ways, the design of bulk shielding is a classical engineering problem; one develops a solution
that comprises an acceptable balance of the competing attributes of safety, utility, and cost.
Broadly, to design shielding one must have knowledge of the stray radiation production,
transport, and attenuation in shielding barriers. In addition, the shielding design goals, i.e. the
permissible exposure rate at an occupied location, depend on the fraction of time an area is
occupied, its designation as a controlled or uncontrolled area, and the type of individuals present, i.e. patients, staff (radiation workers) and the general public. There are typically multiple
design goals to be satisfied, e.g. one for short term exposures (averaged over one hour) and
one for long term exposures (averaged over one year). In general, one does not know a priori
which design goal will ultimately govern the shielding design, necessitating shielding calculations that represent multiple scenarios.
Before discussing the basic physics of shielding design, we digress briefly to point out that
shielding barriers are one of several necessary components of an effective radiation protection program. Shielding barriers alone do not ensure safety. It is impractical, not to mention
prohibitively expensive, to build shields that by themselves provide adequate protection for
unrestricted usage of contemporary proton therapy systems. Administrative controls on beam
usage are therefore necessary and, for obvious reasons, the anticipated beam usage must be
taken into account in the shielding design process. Knowledge of the proton beam usage is
often difficult to predict, particularly for first-of-kind treatment units where neutron production in the beam production and delivery systems are poorly known. In addition, the future
outcome of a clinical trial or a change in health care policy may dramatically change proton
beam usage. Leaving these uncertainties aside, one needs to know not only the beam usage
(energies, charges and currents, and directions of travel) at each of the treatment locations,
but also all of the corresponding proton loss rates in the accelerator, energy selection system
(if present), beam transport system, and treatment head. The loss proton losses and neutron
production vary strongly with the proton beam energy and other factors (see figure 22), necessitating separate calculations for several proton beam energies (Newhauser et al 2002d). Many
aspects of shielding of proton therapy facilities are similar to those for photon therapy facilities, which have been reviewed in detail elsewhere (NCRP 2008).
On the assumption that the beam usage, occupancy factors, and other aspects are known,
one may calculate the neutron dose equivalent rate at a point of interest behind a slab shielding barrier (e.g. wall, ceiling, etc.) that is parallel to and at a distance a the proton beam
according to
⎡ −d ⎤
⎛
d ⎞ Ho(E p, θ )
exp ⎢
⎟=
⎥,
H ⎜E p, θ ,
2
⎝
⎣ λ(θ )g(α ) ⎦
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r
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Figure 22. (Upper) The proton therapy facility treatment level: 235-MeV cyclotron
(1), variable-thickness graphite energy degrader (2), momentum analysis magnets (3),
slits (4), brass collimator (5), and beamstop at isocenter (6). Plan also shows the main
control room (b), treatment room maze exit (m, n, o, a), and various corridors and
occupied rooms on the level above (c–k) (Newhauser et al 2002c). (Lower) Calculated
neutron dose equivalent spectra at locations l–o in the gantry room and its maze (see
figure 1) produced by a 235 MeV proton beam. The ordinate corresponds to the product
of the neutron fluence-to-dose-equivalent conversion coefficient hΦ, the neutron
spectral fluence ΦE, and the neutron energy En, where the product is normalized to the
total neutron dose equivalent H. These spectra reveal differences in the shape due to
the relative contributions from peaks due to thermal neutrons, evaporation neutrons,
and cascade neutrons. The region between 10–6 and 10–2 MeV, corresponding to 1/En
behavior of the spectral fluence, contributes relatively little to the total dose equivalent
(reproduced with permission from Newhauser et al 2002c).

where H(Ep, θ, d/λ) is the ambient dose equivalent beyond the shield, Ep is the proton beam
energy, θ is the emission angle from the proton loss point and the point of interest, r is the
distance between the proton loss point and the point of interest, d is the thickness of the shield,
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λ(θ) is the attenuation length of the shield material, Ho(Ep, θ) is the source term, α is the angle
of incidence of the radiation impinging on the shield, and g(a) is the corresponding obliquity
factor. This semi-empirical approach, based on the work of Moyer (1962), has many attractive attributes, including the inclusion of major dependencies, simplicity, and computational
speed. Five decades on, in spite of its limitations, the Moyer model still is widely used, especially in cases where speed and convenience are more important than accuracy.
Personnel must be able to ingress to and egress from access shielded vaults quickly, e.g. for
efficient routine clinical operation, in emergencies such as attending to a sick patient, and to
maintain and repair the accelerator and beam transport system. This necessitates large openings in the bulk shielding walls. Obviously such openings result in a reduction in attenuation
that must be restored. Typically the required attenuation is restored by fitting the opening with
a long and curved shielding tunnel, commonly referred to as a maze or labyrinth. The maze
attenuates radiation that is incident upon it in two ways: its walls attenuate the deeply penetrating radiation that is incident on the maze walls, and it attenuates the less-penetrating radiation
that enters the opening of the maze by a combination of scattering and absorption processes
as the radiation propagates through of the maze.
Typically the mazes of treatment rooms are not equipped with massive shielded doors
because they can significantly increase access times. On the other hand, infrequently accessed
vaults (e.g. for the accelerator and beam transport system) commonly utilize a maze equipped
with a massive shielding door.
The dose equivalent rate outside the maze (without a door) from scattered radiation that
enters the maze entrance (inside the vault) is given by
H (r1, r2, r3, ..., rn ) =

2a2Ho(a )
r 12

n

∏i = 2 fi (ri ) ,

(46)

where r1 is the line of sight distance from the source to the point of interest in the first (closest
to the source) leg of the maze maze, Ho(a) is the dose equivalent at distance a from the source,
a is distance from the source to the entrance of the first leg, and fi(ri) are attenuation factors
for the subsequent legs of the maze (Agosteo 2009). These are given by
f (ri ) =

e−ri /0.45 + 0.022Ai 1.3e−ri /2.35
,
1 + 0.022Ai 1.3

(47)

where ri is the distance from entrance of the ith leg to the point of interest in that leg,
and where Ai is the cross sectional area of the ith leg of the maze (Agosteo 2009). In
addition, one must still (separately) consider attenuation of radiation impinging upon
the outside of the maze walls (e.g. using the Moyer model) and the attenuation in maze
doors, in cases where they are used. The attenuation of the maze increases with the
number and length of the legs, the thickness of the maze walls, and decreases with cross
sectional area. It would be difficult to overemphasize the high relative importance of the
design of the mazes. Fortunately, there are available several design methods that are well
understood, accurate, and that have been validated with measurements in clinical proton
therapy facilities.
Materials used for the bulk shielding barriers and mazes vary somewhat, depending on the
cost and availability of the shielding materials and the cost of space occupied by the shielding barriers. Typically, ordinary concrete with steel reinforcement is utilized because of its
large hydrogen content and mass density (2.35 g cm−3), high strength, good availability, and
low cost. Contemporary proton therapy centers use concrete shielding barriers of up to several meters thick (Newhauser et al 2002, Titt and Newhauser 2005). The neutron attenuation
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Figure 23. The attenuation length of neutrons in concrete versus proton beam energy
(reproduced with permission from Agosteo et al 2007).

length, or the thickness required to reduce the incident fluence by a factor of 1/e, is plotted
in figure 23 for ordinary concrete. At the high-energy limit, the attenuation length is approximately 50 cm of ordinary concrete (Moritz 2001). The density and attenuating properties of
concrete can be increased substantially by utilizing high-density aggregate material, but its
higher cost prohibitive in most cases. Some facilities have utilized comparatively small ‘local’
shields, e.g. to shield beamline components that produce copious quantities of neutrons, to
lessen the attenuation requirements of larger bulk shields. In some cases, higher density materials such as alloys of iron (7.9 g cm−3) or tungsten (19.25 g cm−3) may be advantageous for
shielding against high-energy neutrons because they can be made more compact than with
concrete or other bulk shielding materials. Proton beam stoppers, which prevent the primary
proton beam from impinging on the bulk shielding, have been made from a variety of materials, including plastic and steel.
The shielding design methods most often used for proton therapy facilities are analytical
formulas and Monte Carlo simulations. The knowledge of the uncertainties in predictions
from both of these methods is incomplete. Newhauser et al (2002c) measured, calculated
(using semi-empirical analytical models that were developed for slab and maze shielding
geometrics), and simulated neutron dose rates at a 235 MeV proton therapy center, and they
found that the analytical model overestimated neutron dose at most positions compared to
measurements, while Monte Carlo simulations agreed more closely with the measurements.
However, the Monte Carlo method is considerably more challenging because of the need to
obtain convergence of solutions; generalized and automated variance reduction techniques are
lacking. Titt and Newhauser (2005) evaluated the uncertainty associated with Monte Carlo
shielding technique by comparing the analytical predictions with detailed Monte Carlo simulations of neutron equivalent doses at various receptor locations. They found the optimum
rejection criterion to be 10% statistical uncertainty for the Monte Carlo simulations. This
rejection criterion provided additional confidence because virtually all accepted simulated
results had converged.
In an unpublished study, one of us (WN) estimated the cost of concrete and steel used for
shielding a typical multi-room proton therapy at approximately 6 M USD, with the potential
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to reduce shielding costs by almost one third through improved neutron shielding designs.
Evidently there is considerable potential to achieve cost savings and other benefits by developing improved shielding design methods and to optimize shield designs.
Although we have not discussed small local shields of beamline components in this section, there is considerable overlap with the material presented in the previous section, for
brevity we shall not consider stray radiation inside of a treatment room here.
7. Challenges and future of proton therapy
The future utilization of proton therapy is difficult to predict. There are some tentative indications that it will continue to become more widely available in developed countries, perhaps
owing to the clear theoretical dosimetric advantages associated with proton beam dose distributions. Perhaps the strongest argument in favor of protons is actually an indirect counter
argument: there is little evidence of beneficial effect from unnecessary irradiation of healthy
tissues (i.e. from the exit dose of photon beams) (Terasawa et al 2009). Other arguments in
favor include an excellent record of treatment safety and efficacy. Furthermore, over the past
15 years, many arguments against proton therapy have been largely or fully disproved, e.g. it is
too complex and too difficult for most clinical organizations, manufacturers cannot be counted
upon to deliver systems on schedule, the range uncertainty is too large, and the risks from stray
neutron doses are too great.
Nonetheless, skepticism and controversy remain regarding the ultimate role of proton
therapy in radiation oncology. Especially in the last few years, the debate seems to focus on
cost-effectiveness and cost-competitiveness. Basically, the argument goes, the cost and value
of proton therapy has not been proven with evidence of improved patient outcomes, which are
presumed to offset some or all of the higher costs of proton therapy systems. If the price differential between proton and photon therapies were to substantially shrink or disappear, e.g.
due to economies of scale, many clinics would replace at least some photon treatment units
with proton units.
For all these reasons, there are many urgent research questions of relevance to proton therapy. Some of these are enumerated here, with an emphasis on those questions that will require
physics research and development to reduce cost, improve treatment quality and efficiency,
and create previously new treatment capabilities of clinical importance.
(a) Can novel techniques, such as proton arc therapy (Sandison et al 1997, Sengbusch et
al 2009, Rechner et al 2012), be developed to improve the quality of treatment, reduce
treatment time, and increase cost-competitiveness and -effectiveness?
(b) Can cost-competitiveness or treatment capability be increased significantly through
incremental improvements to existing accelerator technologies, e.g. fixed-field alternating
gradient synchrotron (Johnstone et al 1999) and superconducting cyclotron accelerators (Blosser et al 1997), or novel linear accelerators, e.g. wakefield laser accelerators
(Schwoerer et al 2006) and dielectric wall accelerators (Caporaso et al 2008)?
(c) Can ultra-compact low-energy proton accelerators provide hand-held or robotically
mounted radiation sources for treating superficial tumors or intra-operative treatment of
deep-seated tumors?
(d) How can range uncertainties be quantified and minimized? In cases where uncertainties are presently too large, what roles will prospective imaging play, including proton
CT (Schulte et al 2004) and megavoltage photon CT (Langen et al 2005, Newhauser
et al 2008a, De Marzi et al 2013)? Similarly, what role will real-time or post-treatment
imaging play, including prompt gamma imaging (Peterson et al 2010, Gueth et al 2013),
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(e)

(f)

(g)
(h)

(i)

positron emission tomography (Parodi et al 2007, Cho et al 2013, Min et al 2013), proton
radiography (Schneider and Pedroni 1995), and magnetic resonance imaging (Krejcarek
et al 2007)?
In the future, what out-of-field dose algorithms should be developed for treatment planning systems used for research or routine clinical practice? Techniques for the calculation
and measurement of therapeutic dose are reasonably well established (with a few exceptions mentioned below). In most cases, intensity-modulation techniques have enabled the
clinician to provide essentially identical dose distributions to the target volumes using
either proton or photon therapy. Consequently, it appears that comparative treatment
planning studies of the future will mainly focus on the radiation exposure of healthy
tissues and on the feasibility of delivering novel treatments. Knowledge of the physics of
stray radiation exposures is incomplete, and most commercial treatment planning systems
neglect or very crudely approximate the out-of-field dose.
What are the optimal strategies for treating moving tumors, especially in the thorax and
abdomen? For example, will scanned beam treatments with target tracking be beneficial?
How should organ motion be measured during treatment? Do the benefits of incremental
margin shrinkage justify increased risk of interplay dose defects? Are there cases where
passively scattered beams are superior?
As the use of on-board imaging is expected to increase, how will additional radiation
exposures to patients be monitored and minimized? Are the radiogenic risks of future
imaging schemes justified by their benefit to the patient?
What is the role of future multimodality radiation therapies that include protons? The
objectives of such protocols include reducing skin dose, sharpening penumbral widths
and distal falloff lengths, and reducing dose delivery errors. Important sources of errors
include temporal interplay of the organ motion and beam location and range uncertainties
due to image artifacts caused by metal implants. Possible implementations could include
a source of protons and other particles, e.g. photons, on a single rotational gantry.
Is there a need for a national or international primary standards laboratory to provide
reference proton beams to support a standard for dose absorbed to water?

In the last 15 years or so, much progress has been made toward a complete understanding
of the physics of proton therapy. In particular, today there exist analytical models and simulation techniques to design and model most of the major aspects of clinical proton therapy
systems currently in operation, several of which we have reviewed in this paper. However,
even with today’s state of the art knowledge of proton therapy, the answers to many questions
of scientific interest and economic importance remain tantalizingly beyond the reach of current research capabilities. As in the past, clinical needs and economic forces will likely define
many of the future research frontiers in proton therapy.
To fully exploit the advantages of proton beams to improve patient outcomes, it is clear that
additional research is needed to optimize the current generation of proton therapy systems,
to make new discoveries and translate breakthroughs into novel prototype research systems,
to obtain a deeper and clinically applicable understanding of the relevant aspects of radiation
biology, to improve the efficiency clinical operations (e.g. industrial and process engineering),
and to generate theoretical and observational evidence to assess the comparative effectiveness
and cost of proton therapy relative to other comparable treatments for a wide variety of diseases, anatomical sites, and outcome endpoints. The relative priority of these goals is a matter
of subjective judgment and speculation, which we shall leave to the reader.
Much of the important research will require experts and specialists from disciplines such
as accelerator physics, imaging physics, various engineering specialties, oncology, biology,
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biostatistics and epidemiology, and computer science. Many basic and applied research studies are well suited to purely academic or clinical research environments and research teams.
Other research studies will benefit from the formation of collaborative teams comprising
members drawn from the academy, medicine, and industry.
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